Evaluation of pharmacological properties and anti-neoplastic potentials of pelargonium iquinans and opuntia stricta extracts using acute leukemia cell lines by Izuegbuna, Ogochukwu Osita
1 
 
EVALUATION OF PHARMACOLOGICAL PROPERTIES 
AND ANTI-NEOPLASTIC POTENTIALS OF PELARGONIUM 
INQUINANS AND OPUNTIA STRICTA EXTRACTS USING 
ACUTE LEUKEMIA CELL LINES. 
 
 
BY 
OGOCHUKWU O. IZUEGBUNA  
A dissertation submitted in fulfillment of the requirements for the 
degree of  
MASTER OF SCIENCE (MSc): BIOCHEMISTRY 
 
 
DEPARTMENT OF BIOCHEMISTRY AND 
MICROBIOLOGY,  
FACULTY OF SCIENCE AND AGRICULTURE,  
UNIVERSITY OF FORT HARE, 
 
SUPERVISOR: PROF G BRADLEY 
Co-SUPERVISOR: DR G.A OTUNOLA  
 
 
 
 
 
2 
 
DECLARATION 
I, Ogochukwu O. Izuegbuna, hereby declare that this research work was carried out by me 
and it has never been submitted for any other degree at this University or any other 
University.   
 
 I declare that I am completely aware of the University of Fort Hare policy on plagiarism and 
I have taken every necessary precaution to comply with the regulations of the University.   
  
 I further declare that I am completely aware of the University of Fort Hare Policy on 
research  
ethics and have taken every necessary precaution to comply with the regulations of the  
University. There was no need for ethical clearance for this work.     
 
  Signature: ………………………………………………………………………..    
 
  Date:        ………………………………………………………………………... 
 
 
 
 
 
 
 
 
3 
 
 
ACKNOWLEDGEMENT 
Acknowledgements and thanks to:  
 To my supervisors Professor G. Bradley and Dr G.A Otunola for their expertise, excellent 
supervision and mentorship, which they provided during this study. Without their assistance 
it could not have been possible to go through this research project;  
 Members of the Medicinal Plants and Economic Development (MPED) Research Centre 
most especially Professor Afolayan,  Dr Wintola,  Dr Ajayi, Mr Unuofin and Mr Ohikhena 
for their assistance, endurance and encouragement; 
 Professor Afolayan for allowing me to use the MPED laboratory;  
 Department of Biochemistry, Faculty of Science and Agriculture, University of Fort Hare 
especially Ms Nqumla for her assistance;  
 The Goven Mbeki Research and Development Centre, University of Fort Hare for the 
financial support ;  
 Finally the Almighty God all the glory and honour for making it possible to  complete this 
course. 
 
 
 
 
 
 
 
 
 
4 
 
 
LIST OF ABBREVIATIONS 
AG Aminoguanidine 
ALL Acute lymphoid leukaemia 
AML Acute myeloid leukaemia 
ASR Age standardized rate 
BSA Bovine Serum Albumin 
CBF Core binding factor 
CD Cluster of differentiation 
CEBPA CCAAT-enhancer binding protein A 
CELEX Celecoxib 
COX 2 Cyclooxygenase 2 
Cyt Cytarabine 
DPPH 1, 1-diphenyl-2- picrylhydrazyl  
DMEM Dulbecco's Modified Eagle Media 
DMSO Dimethyl sulfoxide 
FAB French American British 
FBS Fetal Bovine Saline 
FLT3 Fms-like tyrosine kinase 
g Gram  
GAE Gallic acid equivalent 
GC-MS Gas chromatography mass spectrometry 
H2O2  Hydrogen peroxide  
5 
 
HO•  Hydroxyl radical 
HSCT Haematopoietic stem cell transplant 
IL Interleukin 
iNOS inducible nitric oxide synthase 
kDa Kilo Dalton  
m Milli  
LBP  LPS- binding protein 
LPS Lipopolyssacharide 
M Molar  
MAPK Mitogen associated protein kinase 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MyD88 myeloid differentiation protein-88 
NE No extract 
NO Nitric Oxide  
•NO2 Nitrogen dioxide 
NOPHO  Nordic Society of Paediatric Haematology and Oncology 
NFkB nuclear factor-kappa Beta 
O2
-  Superanion oxide 
ONOO−  Peroxynitrite 
OS Oxidative stress 
PARP poly (adenosine diphosphate-ribose) polymerase 
PBS Phosphate Buffered Saline  
RNS Reactive Nitrogen Species 
6 
 
ROS Reactive Oxygen Species 
RPMI 1640 Roswell Park Memorial Institute 
SD  Standard deviation 
SOD Superoxide dismutase 
TET2 Ten Eleven Translocation 
TRAM TRIF-related adaptor molecule 
TLR4 Toll-like receptor 4 
WCRF World Cancer Research Fund 
WHO World Health Organization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
Abstract 
   Leukaemia  like other cancers is a public health issue, and coupled with the issue of drug 
resistance, toxicity and refractory disease novel treatments both as definitive and supportive 
care become necessary. The dissertation was designed to evaluate two medicinal plants 
(Opuntia stricta and Pelargonium inquinans) and their antineoplastic potentials. The 
phytochemicals analyses were done using standard methods with three different solvents 
(acetone, aqueous and ethanol). Vitamins analyses was also done using standard methods. 
The result revealed that vitamin A,C and E were present in the plants. Cell based anti-
inflammatory activity were carried out using RAW264.7 macrophages cell, and COX-2 and 
NO expression as inflammatory markers. Cell based cytotoxicity and antineoplastic activity 
was investigated using RAW 264.7 macrophages cell, U937 and Jurkat cells.  The results of 
the phytochemical analyses using GC/MS showed that phenols, flavonoids, flavonol, tannin, 
proanthocyanidin, saponin, alkaloids and phytate were present in these plants. In vitro 
antioxidant activity was carried out using nitric oxide (NO), alpha, alpha-diphenyl- β-
picrylhydrazyl (DPPH), hydrogen peroxide (H2O2), phosphomolybdenum activity, and iron 
reducing power (FRAP) techniques. The results of the antioxidant activity showed both 
plants had antioxidant properties that can be attributed to the phytochemical and vitamins 
contents. The results showed that both plants had anti-inflammatory properties which can 
also be attributed to their phytochemicals. The GC-MS analysis of the essential oils of both 
plants showed the presence of monoterpenes, sesquiterpenes, fatty acids, and esters. The 
results showed that O. stricta extracts have mild cytotoxicity, while P. inquinans have strong 
cytotoxicity. The cell cycle analysis showed Pelargonium inquinans extracts induced G0/G1 
phase arrest and cleaved caspase-3. This study has shown the antineoplastic potential of P. 
inquinans which may be attributed to some phytochemicals in it such as carophyllene, 
humulene, beta myrcene and beta pinene.  
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CHAPTER ONE 
1.0 INTRODUCTION 
1.0 Overview of acute leukaemia 
   Acute leukaemia is the proliferation of immature bone marrow-derived cells also called 
blasts in the bone marrow. Leukaemia may also involve peripheral blood or solid organs with 
the clinical sequelae of anemia, thrombocytopenia, and neutropenia attributed to blasts 
induced bone marrow failure and eventual death. Traditionally acute leukemias are classified 
by morphology and cytochemistry into myeloid or lymphoid as proposed by the French 
American British (FAB) Group (Bennett et al., 1976). This classification was later 
supplemented by immunophenotyping alone by the European Group for the immunological 
classification of leukemias (EGIL) (Bene et al., 1995). The World Health Organization 
(WHO) classification, which has been periodically revised to adopt new discoveries, was 
developed to accommodate the failure of the FAB classification to put in perspective the 
distinct nature of myelodysplastic changes in acute myeloid leukemia or other cytogenetic 
abnormalities (Harris et al., 1995; Swerdlow et al., 2008). In the past, the minimum 
percentage of marrow blasts required to make a diagnosis of acute leukemia was 30%, but 
was lowered to 20% for many types of leukemias (MariaStefania, 2011); although some 
cytogenetic abnormalities are diagnosed irrespective of their percentage blasts (Porwit, 2011 
). Currently, modern diagnosis of acute leukaemia involves morphological, immunological 
and molecular/ cytogenetic findings. 
1.1 Acute myeloid leukaemia 
1.1.1. Definition and epidemiology 
   Acute myelogenous leukaemia (AML) is a clonal malignant haematological disease that is 
characterized by 1) proliferation and accumulation of immature myeloid precursors (also 
called myeloblasts) principally in the bone marrow, and most often eventually in the 
peripheral blood; 2) the impaired and decreased production of normal blood cells which 
invariably lead to anaemia, thrombocytopenia, and neutropenia.  
   The decreased production of normal blood cells can lead to haemorrhage (as a result of 
thrombocytopenia), fatigue (as a result of anaemia), and infections (as a result of 
granulocytopenia). These clinical features are the usual presentations in an AML patient. 
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   The incidence of acute leukemia varies throughout the world with respect to age, gender, 
and ethnicity. The incidence of AML is most common among Caucasians (Jemal et al., 
2002), and accounts for approximately 35% of all adult leukaemias in the United States, 
making it the most common leukaemia in adults (Liesveld, 2016). The worldwide total 
leukemia incidence of AML for 2012 was estimated to be 351,965 with an age-standardized 
rate (ASR) per 100,000 of 4.7, a 5-year prevalence of 1.5% and an M: F ratio of ~1.4 
(GLOBOCAN, 2012).  
   In countries with "medium human development," the 2012 incidence was 136,378 with 
ASR of 3.8 per 100,000, while in countries of "low human development the incidence was 
26,004 with ASR of 2.5 per 100,000. Mortality was 265,461 worldwide with ASR of 3.4 per 
100,000, with a mortality of 113,783 and ASR of 3.2 per 100,000 in countries with "medium 
human development" and 23,865 and ASR of 2.4 per 100,000 in countries of "low human 
development.” It is estimated that in the United States, 21,380 new cases of AML and about 
10,590 mortalities will occur in 2017 (Howlader et al., 2016). In many African countries, the 
incidence of acute leukemia (either myeloid or lymphoid) is not known. However, the 
outcome is dismal. In South Africa, the incidence rate is equally not known, because the 
National Cancer Registry does not make provision for the reporting of the different types of 
leukaemia, neither is there a differentiation between acute and chronic leukemia (CANSA, 
2016).    
1.1.2. Aetiology and pathogenesis 
   Like all other cancers, acute myeloid leukaemia (AML) is a molecular disease which is the 
result of a sequence of somatic mutations in a primitive multipotential hematopoietic cell 
(Liesveld, 2016). For leukemogenesis to occur, the susceptibility of haematopoietic 
progenitor cells [CD34+, CD38-, CD45RA+, CD 90-] to inductive agents at multiple stages is 
required (Van Galen et al., 2014). These haematopoietic cells are multipotential progenitors 
or occasionally, a more differentiated, more lineage-restricted progenitor cell (Fiaklow et al., 
1991). However, they are not pluripotential. There is strong evidence that AML cases arise 
from one to two predominant CD34+ cell populations: CD34+CD45RA+CD38-CD90- 
(multipotential myeloid progenitor) or CD34+CD38+CD45RA+CD110+ (granulocyte-
monocyte progenitor).    Both cell populations correspond to the normal haematopoetic 
progenitor cell, but not the pluripotential haematopoetic stem cell (Gordon et al., 2011).  
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However, there is evidence that accumulation of genetic and epigenetic changes can 
transform a normal pluripotential stem cell into an AML cell (Pandolfi et al., 2013).  
   For a myeloid cell to become malignant, a somatic mutation must occur which most often 
result from a chromosomal translocation. The translocations usually involve a proto-
oncogene with the fusion of the portion of another gene. The fusion of portions of two genes 
usually does not prevent the processes of transcription and translation. Therefore, a new 
fusion protein can be formed with an abnormal structure which can disrupt normal cellular 
pathway at different stages that are involved in controlling growth rate, proliferation and 
survival of blood cell progenitors predisposing the cell to malignant transformation (Liesveld, 
2016). These mutations are usually random and can involve critical regions of the genes. 
Examples of such genes include core binding factor (CBF), retinoic acid receptor-α (RAR-α), 
HOX family, mixed-lineage leukemia (MLL), CEPBA (CCAAT-enhancer binding protein A), 
and other genes. Based on the Knudson two-hit hypothesis (Chial, 2008), these primary 
mutations are not enough to cause a malignant transformation, and will thus need additional 
mutations in such factors like Fms-like tyrosine kinase (FLT)3 and KIT to induce a 
proliferative advantage in such cells. 
   Only four environmental factors have been established as causal agents of AML. They 
include high-dose radiation exposure, (Tsushima et al., 2012) chronic tobacco smoking 
(Lichtman, 2007), chronic high-dose benzene exposure (≥40 parts per million [ppm]-years), 
(Johnson et al., 2009) and chemotherapeutic (DNA-damaging) agents (Larson, 2005;Yeasmin 
et al., 2008). Obesity is another factor that has been linked especially to acute promyelocytic 
leukaemia. The precise mechanisms are not clear, but they could be related to the levels of 
leptin and adiponectin and some unknown factors (Lichtman, 2010; Mazzarella et al., 2016). 
However, most patients have not been exposed to a prior environmental factor. The other 
conditions that increase the risk of AML are mainly genetic factors (Table 1).  
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Table 1: Selected causal factors associated with acute myeloid leukemia.  
Source: Deschler B, Lubbert M, 2006. 
 
Genetic disorders Down syndrome 
Klinefelter syndrome 
Patau syndrome 
Ataxia telangiectasia 
Shwachman syndrome 
Kostman syndrome 
Neurofibromatosis 
Fanconi anemia 
Li-Fraumeni syndrome 
Physical and chemical exposures Benzene 
Drugs such as pipobroman 
Pesticides 
Cigarette smoking 
Embalming fluids 
Herbicides 
Radiation exposure Nontherapeutic, therapeutic 
radiation 
Chemotherapy Alkylating agents 
Topoisomerase-II inhibitors 
Anthracyclines 
Taxanes 
 
 
 
1.1.3. Diagnosis and Classification 
   Clinical features are vague and unreliable in the diagnosis of AML. Presenting features 
such as lethargy, fatigue, pallor, palpitation, dyspnoea on exertion reflects anaemia; 
Petechiae, gingival bleeding, epistaxis, hyphaema are signs and symptoms of 
thrombocytopenia, while fever and minor pyogenic infections indicate neutropenia. Palpable 
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splenomegaly and hepatomegaly are present in about 50% of patients at diagnosis, although 
some other studies have higher values (Shoome et al., 1985; Preethi, 2014; Chang et al., 
2016). Lymphadenopathy is uncommon unlike in acute lymphoblastic leukaemia (Chang et 
al., 2016), except in monocytic variants of AML. Leukemic blasts are also known to invade 
other organs and tissues of the body- chloromas, which is also more common in monocytic 
variants of AML (Hejmadi et al., 2008). Tissues usually involved include the skin (Cibull et 
al., 2008), gastrointestinal tract (Ahsan, 1988; Khatti et al., 2004), the urogenital system 
(Vanden Broecke et al., 1996).  Some of these signs and symptoms are found in many other 
clinical conditions; hence a diagnosis of AML goes beyond clinical features.  
   Diagnosis of AML like other cancers is laboratory based.  A complete blood count and a 
peripheral film smear are most often the first line tests. AML will invariably show an 
abnormality on complete blood count. Anaemia is practically a constant feature (Mathur et 
al., 1993; Preethi, 2014), along with thrombocytopenia. About 50% of patients have a platelet 
count of less than 50,000mm3 (normal- 150,000 - 400,000mm3) (Rowe, 1983) along with 
some platelet abnormalities (Psaila et al., 2011). Total leukocyte count can be high, low or 
normal (Preethi, 2014), as a result of myeloblasts numbers and activity and not a reflection of 
normal leukocyte count. The absolute neutrophil count is usually low, but rarely there may be 
normal counts. The peripheral blood smear can be said to be the backbone of diagnosis of 
AML against the backdrop of more sophisticated tests. It can be used in most cases to provide 
specific, provisional and limited differential diagnosis in the morphological classification of 
AML (Abdusalam, 2011). The peripheral blood smear alone will not suffice without the bone 
marrow aspirate and biopsy (in cases of dry taps) in most cases. The bone marrow aspirate is 
always required for confirmation of a diagnosis of AML and is also required for the 
classification and application of special techniques including cytochemical stains, genetic 
studies, immunocytochemistry and immunohistochemistry (Bain, 2001). To, therefore, make 
a diagnosis of AML demonstration of three criteria are required using the bone marrow 
aspirate.  
 
i. The presence of more than 30% (the older The French American British (FAB) standard 
(Bennett et al., 1976, Bennett et al., 1985)) or 20% (the newer WHO standard (Swerdlow et 
al., 2008)) leukemic blasts in a bone marrow aspirate. 
 
ii. The detection of myeloid differentiation either by histochemistry or by analysis of myeloid 
membrane molecules usually by flow cytometry. 
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iii. Sub-classification according to (a) the FAB  (Table 2) that is based on morphology and 
histochemistry; or (b) a more detailed classification based on morphological characteristics 
together with clinical history (de novo or secondary leukemia) and genetic analysis in 
accordance with the new WHO classification (Table 3). 
TABLE 2: French American British classification of acute myeloid leukemia 
Source: Slideshare.net 
 
FAB 
Type 
Description Incidence Morphology Cytochemistry 
M0 Minimally 
differentiated 
2 Blasts lack definite 
cytologic and 
cytochemical features but 
have myeloid antigen 
lineage.  
Myeloperoxidase neg. 
M1 without maturation 20 Myeloblast predominate. 
few granules/Auer rods 
Myeloperoxidase + 
M2 with maturation 30 Myeloblasts with 
promyelocytes present. 
few Auer rods 
Myeloperoxidase +++ 
M3 Acute promyelocytic 
leukaemia. 
5 Multiple promyelocytes 
with multiple Auer rods 
Myeloperoxidase +++ 
M4 acute myelomonocytic 
leukaemia 
30 Blasts with both myeloid 
and monocytic series 
Myeloperoxidase +++ 
Nonspecific esterase + 
M5 acute monocytic 
leukemia 
10 M5a show poorly 
differentiated, M5b shows 
differentiated. 
Nonspecific esterase 
++ 
M6 Acute erythroleukemia <5 >50% erythroblast. 
myeloblast also raised. 
PAS+  
Myeloperoxidase + 
M7 acute megakaryocytic 
leukaemia 
<5 Pleiomorphic 
undifferentiated blast 
reacts with platelet 
antibodies  
Platelet peroxidase + 
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TABLE 3: World Health Organization classification of acute myeloid leukemia (AML) 
and related precursor neoplasms 
Source: Blood and Bone marrow pathology, 2nd ed.2011 
AML with recurrent genetic abnormalities  
 AML with t (8; 21) (q22;q22); (RUNX1-RUNX1T1)  
 AML with inv (16) (p13.1q22) or t(16;16)(p13.1;q22); (CBFB-MYH11) 
 Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12);  (PML-RARA)  
 AML with t (9; 11) (p22; q23); (MLLT3-MLL)  
 AML with t (6; 9) (p23; q34); (DEK-NUP214)  
 AML with inv (3) (q21q26.2) or t (3; 3) (q21; q26.1); (RPN1-EVI1)  
 AML (megakaryoblastic) with t (1; 22) (p13; q13); (RBM15-MKL1)  
 AML with mutated NPM1 (provisional) AML with mutated CEBPA (provisional) 
 
AML with multilineage dysplasia 
Following MDS or MDS/MPD 
Without antecedent MDS or MDS/MPD, but with dysplasia in at least 50% of cells in 2 or more myeloid lineage 
 
AML with myelodysplasia-related changes Therapy-related myeloid neoplasms  
Alkylating agent/radiation – related type 
Topoisomerase II inhibitor-related type 
Others 
 
Acute myeloid leukemia, not otherwise specified (NOS)  
 AML with minimal differentiation  
 AML without maturation  
 AML with maturation  
 Acute myelomonocytic leukemia  
 Acute monoblastic and monocytic leukemia  
 Acute erythroid leukemia Pure erythroid leukemia Erythroleukemia, erythroid/myeloid  
 Acute megakaryoblastic leukemia  
 Acute basophilic leukemia  
 Acute panmyelosis with myelofibrosis  
Myeloid sarcoma  
Myeloid proliferations related to Down syndrome  
 Transient abnormal myelopoiesis 
 Myeloid leukemia associated with Down syndrome  
Blastic plasmacytoid dendritic cell neoplasm 
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   AML is a heterogeneous disease; therefore classification into its variants is both essential 
and part of the diagnostic process. Traditionally, AML is sub-classified into eight subtypes, 
M0-M7 according to the FAB morphological classification (Table 2). These subtypes are 
classified based on myeloid lineage involvement and degree of varieties of leukemic cell 
differentiation. Light microscopy (using Wright- Giemsa or May- Grunwald- Giemsa 
staining) and cytochemistry (Myeloperoxidase, Sudan Black, Non-Specific esterase, 
chloroacetate esterase) is the standard method required.  All the subtypes can be diagnosed 
using light microscopy and cytochemistry except for M0 which can only be diagnosed via 
immunophenotyping. 
    Immunophenotyping is a technique used in localizing proteins in tissue sections and cell 
suspensions by using antibodies directed against the antigen and visualizing the antibody-
antigen reaction that follows. It is used in differentiating the M0 subtype of AML from Acute 
lymphoblastic leukaemia (Jaffe et al., 2001). In addition to determining myeloid lineage, it 
can be used to differentiate monocytic, erythroid and megakaryocytic lineages of AML as 
well as promiscuous ones, i.e., biphenotypic leukaemias. It can also be used to prognosticate, 
though cytogenetics and molecular genetics seem to play a more prominent role. 
Immunophenotyping can be performed by flow cytometry, and also by 
immunohistochemistry on slides. The EGIL use immunophenotyping solely to classify 
leukaemias. The advantage immunophenotyping (immunologic classification) has over the 
FAB morphologic classification is that it is not subjective, neither is it given to observer 
variation; thus it is reproducible. Both coupled together can improve diagnosis. For practical 
purposes, the use of morphology and immunophenotyping is sufficient to diagnose AML.   
   Cytogenetics and molecular markers are changing the diagnostic landscape of leukaemias, 
and are even influencing a treatment decision. They can be used to diagnose as well as 
prognosticate AML. Patients with mutations of the CBF that are cytogenetically classified as 
t (8:21), t (15; 17), t (16; 16), and inv 16 do not need to meet the 20% blast criteria to be 
diagnosed with AML (Porwit et al., 2011). About 50- 70% of patients with de novo AML 
have one of chromosomal abnormality (Smith et al., 2004), and those with the CBF mutations 
are considered to have a favourable outcome. However, this may not be entirely true because 
of its inability to detect small size aberrations or cryptic translocations, for example, NUP98-
NSD1, CBFA2T3-GLIS2, and MNX1-ETV6, which predict a poor outcome in pediatric 
AML (Grimwade, 2011; Gruber et al., 2012 ). It also does not provide insights into molecular 
mechanisms underlying AMLs with numerical or other structural changes, or importantly, 
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those with normal karyotype, which account for about 40% of adult AML and are highly 
heterogeneous regarding clinical outcome (Grimwade et al.; 2016). For example, patients 
with some CBF  mutations, e.g., inv (16)/ t (16:16) may also have RUNX1/ RUNX1T1 and 
CBFB/ MYH11 oncogenes (Cox et al., 2003). However, some express an additional KIT 
mutation which bears a worse prognosis (Paschka et al., 2006). In t(8;21) leukemias, 
epigenetic silencing of microRNA-193a is known to activate the PTEN/PI3K signaling 
pathway (Li et al.,. 2013).  Wild-type RUNX1 can also influence nuclear factor-kappaB (NF-
κB) signaling, events not present in the t(8;21) translocation leukemias (Nakagawa et al., 
2011). However cytogenetic and molecular analyses of FLT3 ITD, NPM-1, CEBPα, and KIT 
mutation status in CBF leukemias should be determined, if available. 
   There are about nine categories of genes relevant to the pathogenesis of AML in those that 
are apparently cytogenetically normal (Cancer Genome Research Network, 2013). With the 
use of molecular genetics techniques (PCR based methods, Gene sequencing) such genes are 
being elucidated and are seen as possible druggable targets. Just recently, Rydapt® was 
approved by the Food and Drug Administration (FDA) for the treatment of Flt3 positive 
AML (Novartis, 2017). Currently, the use of molecular genetics techniques is complementary 
to conventional cytogenetics for risk stratification of acute leukemias.  
 
1.1.4 Treatment of AML 
  The management of AML can be divided into two, namely: definitive and supportive. The 
definitive management is the bedrock of care and consists of a combination chemotherapy 
regimen and haematopoietic stem cell transplant (HSCT). The initial treatment is called 
remission induction, and the goal is to reduce the leukemic cells to below the cytologically 
detectable level of approximately 109 cells. This treatment is followed by another phase of 
chemotherapy called the postinduction or remission consolidation therapy. The goal of this 
phase is to eradicate residual leukemia cells and thereby prevent later relapse. Remission, in 
this case, can be defined as elimination of the leukemic cell population in marrow as 
ascertained by microscopy and flow cytometry and the restitution of marrow hematopoiesis 
resulting in a normal or virtually normal white cell, hemoglobin, and platelet concentrations 
in the blood (Liesveld, 2016). Complete remission which is the goal of remission induction 
therapy is said to be achieved when percent blasts in the marrow are <2%, a neutrophil count 
greater than 1000/μL, and a platelet count greater than 100,000/μL (Cheson et al.; 2003). 
Many patients do enter complete remission with remission induction therapy. However, most 
of them do relapse and may need a different treatment regimen or enter clinical trials. 
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   The standard chemotherapy used in remission induction phase of non-APL AML is 
cytarabine given by continuous intravenous (IV) infusions (100 mg/m2 per day) for seven 
days plus daunorubicin (45 to 90 mg/m2 by intravenous short-time infusion) daily for the first 
three days; the popular “7+3” regimen. Remission rate with this regimen is reported to range 
between 55- 90%. If induction fails, a reinduction with the same regimen can still be given. 
About 40% of patients that fails the 1st course do achieve remission with a reinduction course 
(Schlenk et al., 2003). Other regimens have been tested, but with variable results and 
increased toxicities. For example, patients receiving high-dose cytarabine for remission 
induction do have a higher complete remission rate (Weick et al., 1996; Lowenberg et al., 
2011), but increased leukopenia, thrombocytopenia and eye toxicity (Liesveld, 2016).  
  Haematopoietic cytokines like granulocyte colony-stimulating factor (G-CSF) has been used 
in untreated leukaemic patients to sensitize the blasts by increasing the numbers in the DNA 
synthetic phase, therefore, rendering them more sensitive to chemotherapy (Lowenberg et al., 
2003; Thomas et al., 2007). A study showed a decrease in relapse rate when G-CSF was 
combined with a chemotherapy regimen as against when not used (Lowenberg et al., 2003).  
   The goal of postremission therapy is to prolong the state of remission and overall survival. 
There are normally three choices for postremission chemotherapy: consolidation 
chemotherapy, allogeneic HSCT, and autologous HSCT. There is no consensus on which is 
of more benefit. In a randomized trial, allogeneic transplantation was compared to autologous 
transplantation in patients who had a complete remission after induction chemotherapy. 
Disease-free survival was 53 percent at four years for those receiving allogeneic 
transplantation, 48 percent for those receiving autologous transplantation, and 30 percent for 
patients receiving intensive chemotherapy (Zittoun et al., 1995). But there is no significant 
difference in the disease-free survival among the three choices (Harrousseau et al., 1997). 
The choice of postremission therapy either autologous or allogeneic HSC transplantation or 
intensive chemotherapy alone for consolidation should be individualized; this should be 
based on the patient’s age and other prognostic factors, such as high-risk cytogenetic findings 
and antecedent hematologic disease. Patients with good-risk cytogenetics can be given up to 
four cycles of intensive chemotherapy, while patients with poor-risk cytogenetics can be 
considered for allogeneic HSCT as soon as feasible.  
    Intensive consolidation therapy can be the same drugs used in induction phase or a 
different regimen. Regimens containing high-dose cytarabine (HiDAC) are usually preferred 
and show better benefits than intermediate-dose cytarabine (Heil et al., 1995). About four 
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cycles can be given, but patients that are for allogeneic HSCT are better off with that as they 
will not benefit from even a single cycle (Cahn et al., 2000). Patients with favourable 
cytogenetics especially the CBF  mutations benefit more from HiDAC than others (Stone, 
2013), most especially if gemtuzumab ozogamicin, the anti- CD33 antibody-calicheamicin 
conjugate is added (Petersdorf et al., 2009). Those with RAS mutations equally benefit 
(Neubaeur et al., 2008). HiDAC can cause conjunctivitis, photophobia, and cerebellar toxicity 
(Momparler, 2013). Patients older than 60 years or with renal insufficiency require dose 
attenuation (Smith et al., 1997). 
   Stem cell transplantation can be divided into two: allogeneic and autologous. Allogeneic 
hematopoietic stem cell transplantation (allo-HSCT) involves related (preferably a human 
leukocyte antigens (HLA)-identical sibling or an HLA-matched relative) or unrelated donor 
with the same HLA as the recipient. HLA genes can be classed into two types; Type I (e.g., 
HLA-A, HLA-B, and HLA-C) and Type II (e.g., HLA-DR, HLA-DQB1). In a situation 
where there is no complete match, a partially matched donor can be considered. However, 
this will increase the risk of graft rejection or severe graft-versus-host (GVH) disease. One 
advantage allo-HSCT has is that the donor T cells can produce a specific graft-versus-
leukaemia (GVL) immune response, that can aid in the eradication of remaining leukaemia 
cells. There are no age limits for allo-HSCT. However, most centers use age 60 to 65 years 
for the myeloablative procedure and 70 to 75 years for non-myeloablative procedures. Such 
decisions should, however, be individualized and be based on (a) the availability of a suitable 
donor, (b)the recipient’s age and health status, and (c) whether AML is in remission. Allo-
HSCT has superior relapse-free survival, and overall survival for cases of AML classified 
intermediate and poor risk compared to nonallogeneic therapies (Stelljes et al.,2013). This 
does not apply to cases considered as good risk AML in first remission (Koreth et al., 2009). 
The process in autologous HSCT (auto-HSCT) differs from allo-HSCT. In auto-HSCT, the 
patient's stem cells when isolated are cryopreserved and reinfused to the patient's own body 
after myeloablative therapy. It is often used in patients who have achieved remission but do 
not have a compatible stem cell donor. The advantages of auto-HSCT are it can safely be 
used in patients over 70 years, and it has low treatment-related mortality. However, relapse 
rates are relatively high (30-50%). Overall outcomes after auto-HCT are not better than for 
patients who receive conventional chemotherapy (Tsimberidou et al., 2003; Nathan et al., 
2004). 
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1.2 Acute Lymphoblastic Leukaemia 
1.2.1. Definition and epidemiology 
   Acute lymphoblastic leukaemia (ALL) is a neoplastic disease that occurs from multistep 
somatic mutations in a single lymphoid progenitor cell at one of several discrete stages of 
development;  which results in the clinical sequelae of anaemia, thrombocytopenia, and 
neutropenia. Just like in AML, the lower threshold of blast count (called lymphoblasts) is 
20%. 
   The incidence of ALL is not fixed but varies across age and geographical locations. It is the 
most common cancer among children below the age of 15 years. According to the 
International Classification of Childhood Cancers, acute leukaemias comprise of about 31% 
of all childhood cancers (Kaatsch, 2010), with ALL making up the single largest proportion 
of all childhood malignancies at about 27% of that number. It also accounts for 76% of all 
leukaemias in people below the age of 15 years (Larson, 2016). ALL is known to be higher in 
countries with higher socioeconomic levels (Mejia Arangure et al., 2011), with the lowest 
incidence reported in Asian and African populations (Ferlay et al., 2010). The highest 
incidence of ALL is found among Hispanics (Barrington- Trimis et al., 2015; Barrington- 
Trimis et al., 2017 ) especially in Mexico and Costa Rica (Perez- Saldivar et al., 2011). They 
also have one of the lowest survival rates (Hunger et al., 2012). According to the SEER 
report based on case diagnosed between 1975 and 2010, the age-adjusted incidence of ALL 
among males and females in the United States is 1.6 and 1.2 per 100,000 per year 
respectively (SEER, 2014). It is estimated that 5970 cases will be diagnosed in the United 
States with about 1440 deaths in 2017 (Howlader et al., 2016). ALL cuts across all age group, 
but it has a bimodal incidence; the risk is highest in children under five years of age, declines 
slowly till the mid-20s, then slowly begin to rise after age 50. The incidence is 7.9 per 
100,000 for children 1 to 4 years of age, and 1.2 per 100,000 for adults over 60 years (Larson, 
2016). Like in AML, the incidence rate of ALL is not known in many African countries. In 
South Africa, the incidence rate is equally not known, and this is because the National Cancer 
Registry does not make provision for the reporting of the different types of leukaemia neither 
is there a differentiation between acute and chronic leukemia (CANSA, 2016).    
1.2.2. Aetiology and pathogenesis 
   Acute lymphoblastic leukaemia has no known etiologic factors, unlike AML. Different 
factors have been proposed but without much evidence. While high-dose radiation exposure 
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has been implicated in AML (Tsushima et al., 2012), the same does not apply to ALL. The 
association between the development of ALL and exposure to occupational or cosmic 
ionizing radiation is at best weak (Larson, 2016) although with some exceptions (Kim et al., 
2017). Also, a study done by Kabuto et al. showed evidence that exposure to the high 
magnetic field was linked with a higher risk of childhood leukaemia especially ALL (Kabuto 
et al., 2006). Even with that, consistency of different findings of the association between 
magnetic field exposure and ALL still makes the evidence weak (Pelissari et al., 2009). Other 
interesting findings have been shown in recent times including increasing maternal age 
(Dockerty et al., 2001; Ezzat et al., 2016), maternal educational level (Johnson et al., 2008; 
Ezzat et al.,2016),Caesarean section (Ezzat et al., 2016) and paternal age <20 years (Druley et 
al., 2013).  However in most cases of ALL the etiologic factors are not discernible. The most 
acceptable concept of leukemogenesis of ALL is the complex interaction between 
environment and multiple genetic factors (Mejia-Arangure et al., 2013). Some of these 
theories are based on childhood infections and immune susceptibility. An example includes 
the delayed infection hypothesis proposed by Greaves (Greaves, 1988; Maia, 2013) that early 
encounters with common infections help develop the immune response and may play a role 
against ALL. Greaves has also expanded his hypothesis by adding the most common 
chromosomal aberrations, hyperdiploidy and ETV6- RUNX1 as susceptibility factors, and 
has been incorporated into a minimal 'two hits' model to explain the development of pre-B 
cALL (Greaves, 2002).According to this model hyperdiploidy and the ETV6- RUNX1 
translocation develops in utero that provides the first oncogenic hit and gives rise to a 
preleukaemic clone. This first hit is insufficient to cause the disease.  
   Additional postnatal oncogenic hits are needed for evolution into a malignant leukaemic 
clone. Such clones come about by apparent immune response to microbial infection in 
children raised in hygienic environments. The hypotheses have been put to the test and have 
produced contrasting results (Gilham et al., 2005; Roman et al., 2007).  A host of other 
infectious theories has also been proposed including the population mixing hypothesis 
proposed by Kinlen (Kinlen et al., 1993; Kinlen, 2004). It states that clusters of childhood 
ALL are as a result of exposure of susceptible individuals to common infections when they 
'mix' with carriers in their environment (Kinlen, 2004).  However, not all childhood ALL 
develop in utero. The t (1; 19)/TCF3-PBX1 ALL seems to have a postnatal origin in most 
cases (Wiemels et al., 2002), and Adult ALL develops over a prolonged period.  
   The precise pathogenetic mechanisms in the leukemogenesis of ALL are largely unknown. 
However, like other cancers, it is known that a multistep process of mutations in several 
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oncogenes leads up to malignant transformation. ALL is also a heterogeneous disease like 
AML, and it involves changes in cellular morphology, genetic lesions and rate of 
proliferation. Acquired genetic abnormalities are very common in ALL. About 80% of ALL 
cases have recurring cytogenetic or molecular abnormalities (Mullighan, 2012; Inaba et al., 
2013). Some of these changes include numeric (ploidy) and structural abnormalities in 
chromosomes (Moorman et al., 2010). The latter include inversion, deletions, translocations, 
amplifications and point deletions. Mechanism of actions of these abnormalities is usually 
through oncogene activation, signal transduction through active kinases (e.g., tyrosine 
kinases), and resistance to apoptosis.  These actions do happen pari passu to enhance 
malignant transformation. Just like the Knudson two-hit hypothesis proposed, a single 
mutation is insufficient to cause ALL. Cooperative mutations are usually required. Some of 
these mutations are prognostic and can direct therapy. Some techniques have been applied to 
elucidate these genetic alterations and their cryptic lesions. For example,  BCR-ABL1–like B-
cell ALL lacks the BCR-ABL1 fusion or t(9;22) by cytogenetic, fluorescence in situ 
hybridization (FISH), or molecular analyses, but on gene expression profiling it has similar 
molecular characteristics with typical BCRABL1– positive ALL (Harvey et al., 2010). In 
about one-half of these cases, the CRLF2 gene is involved in a cryptic translocation with the 
IGH gene or is fused to the P2RY8 gene; both rearrangements lead to overexpression of 
CRLF2 (Mullighan et al., 2009). Genes involved in encoding regulatory proteins of normal 
lymphoid development were discovered using single nucleotide polymorphism (SNP) 
microarray and copy number alterations (CNAs). PAX5, a lymphoid transcription factor that 
is involved in encoding a paired-domain protein required for the pro–B-cell to pre–B-cell 
transition and B-lineage fidelity, was one of the genes identified. The IKZF1 which encodes 
The IKAROS zinc finger DNA binding protein that is needed in the earliest development of 
lymphoid differentiation. IKZF1 is known to be deleted in the majority of cases of BCR-
ABL1 ALL cases as well as chronic myeloid leukemia in lymphoid blast crisis (but not 
chronic phase) (Mullighan et al., 2008).  These two (PAX5 and IKZF1) are seen in B cell- 
ALL. In T cell ALL, c-MYC, NOTCH, Hox11, and HOX11L2 have been implicated. The 
NOTCH family of proteins consists of transmembrane receptors with extracellular EGF 
(epidermal growth factor) domain. They are involved in the regulation of proliferation, 
differentiation, and apoptosis in many cell groups including T cells. In the development of T 
cell ALL, NOTCH is known to be involved in downstream signaling pathways through 
transcriptional regulation of their target genes. Some of these pathways are believed to be 
intermediate signaling routes such as phosphatidylinositol 3-kinase (PI3K), Akt / protein 
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kinase B, extracellular signal-regulated kinase-1/2, and nuclear factor-kB (Chan et al., 2007). 
Notch target genes include cyclin D1 and c-Myc which are involved in cell cycle progression 
and cell proliferation. Depending on certain variables like cell type and intensity of the signal, 
Notch signals can be transmitted as pro-oncogenic or tumor suppressor (Leong and Karsan, 
2006). Notch signaling is also known to work in tandem with the signaling of T cell receptors 
(TCR) to expand the number of thymocytes undergoing β-selection. More than 50% of T-cell 
ALL have activating mutations in Notch1. (Gomez et al., 2012). Table 4 below shows a list 
of common mutations in ALL. 
 
1.2.3. Diagnosis and classification 
   Just like in AML, the clinical presentation of ALL is imprecise. The clinical sequelae are 
similar to AML. There is lethargy, pallor, fever and bleeding. Fever may be a result of 
infection due to neutropenia, or cytokines released by the leukaemia cells, e.g., interleukin 1 
and tumour necrosis factor. Such fever does resolve 72hours after the commencement of 
chemotherapy. More than a quarter of patients present with arthralgia and arthritis which can 
mimic Rheumatic syndromes (Esen et al., 2011; Tamashiro et al., 2011), which is most often 
as a result of leukaemic infiltration of the periosteum, bone or joint or due to the expansion of 
the marrow cavity by the leukaemic blasts. This results in bone pain and difficulty in 
walking. Bleeding can occur as a result of thrombocytopenia. Less common signs like 
headaches and an altered mental state may be as a result of intracranial haemorrhage. Such 
bleeding is usually as a result of hyperleukocytosis (Lowe et, 2005). Extramedullary sites 
involvement such as lymphadenopathy, splenomegaly, and hepatomegaly is common in ALL 
(Terwilliger, 2017). Others such as anterior mediastinal mass are less common and can lead 
to superior vena cava syndrome (Larson,2016). Other rare sites include the skin (leukemia 
cutis), the salivary gland (Mikulicz syndrome), tonsils and adenoids (Yamazaki et al., 2002), 
and sanctuary sites like the ovaries and testes (Kim et al., 2008; Kulkarni et al., 2010). 
   Like in other leukaemias, diagnosis is laboratory based. A complete blood count and a 
peripheral film will invariably show anaemia, thrombocytopenia, and neutropenia depending 
on the severity which is a reflection of marrow suppression by leukaemic lymphoblasts (Pui 
et al., 2006).In children about 80% have anaemia less than 10g/dl which is most times 
normochromic, normocytic; thrombocytopenia is about 75%, and they rarely bleed unless 
platelet count is less than 20,000mm3 (Guenova, 2013). Hyerleucocytosis can be seen in 
about 10% to 30% of adults with ALL as compared to AML 5% to 13% (Kong et al., 2014). 
Diagnosis is made through the examination of bone marrow aspirate with a lymphoblast 
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count greater than 20% of all nucleated cells (Alvarnas et al., 2015). Other tests such as 
immunophenotyping, cytogenetics, and molecular genetics are valuable for confirming the 
diagnosis, e.g., immunophenotyping can be used to differentiate between AML FAB M0 and 
ALL. They can also be used for risk stratification and to guide therapeutics. A lumbar 
puncture and CSF analysis is a standard for diagnosis of CNS leukaemia. The international 
definition of overt CNS leukemia is the presence of a WBC count of 5/μl or more in the CSF 
with documented lymphoblasts and/or the presence of a cerebral mass or cranial nerve palsy 
(Laningham et al., 2007).  
   The heterogeneity of ALL makes classification imperative. ALL can be classified using 
morphology, immunology or cytogenetics/molecular genetics. The morphological 
classification was created based on certain criteria like cell size, vacuolation, cytoplasm, and 
nucleoli by the FAB group (Bennett et al., 1976). They are divided into three subtypes- L1, 
L2, L3 based on the criteria above (Table 5; Fig. 1 A, B& C). About 85% of children have 
the L1 subtype, 14% have L2, and 1% have L3 (Guenova, 2013). Immunologic classification 
is based upon the principle that stage of lymphocyte maturation can be used to determine 
subtypes using a panel of antibodies (Table 6). They are divided into B and T cell lineage 
depending on the antigen expressed. The B lineage AL which makes up about 80% of 
paediatric cases, can be subdivided as early pre-B, pre- B, transitional pre-B, and mature B. 
The T lineage ALL can be subdivided according to the stage of normal thymocyte 
development into pro-T, pre-T, cortical or mature T (Bene et al., 1995). The immunologic 
classification has both prognostic and therapeutic importance (Pui et al., 2010). For example, 
the addition of anti- CD20 drugs to combination chemotherapy has been shown to be 
beneficial either as frontline therapy or salvage regimen (Thomas et al., 2010, Jabbour et al., 
2013; Terwilliger et al., 2017). Those of prognostic importance are T cell and mature B cell 
lineage. Another subtype of the T cell lineage with retained stem cell-like features named 
early T cell precursor ALL has been identified and linked with dismal prognosis when treated 
with conventional chemotherapy (Coustan- Smith et al., 2009; Tsunemine, 2015).  
   The use of cytogenetics and molecular genetics to classify ALL has yielded more biological 
information than other methods. About 75% of all ALL cases can be subtyped into the 
relevant prognostic and therapeutic groups based on modern genetics methods alone 
(Mullighan et al., 2007; Pullarkat et al., 2008; Inaba et al, 2013). It forms the basis of the 
WHO classification (Table 7). The favourable prognostic group includes hyperdipoidy which 
occur in 25% of paediatric cases, trisomies 4,10 and 17, t(12;21)(p13.2;q22.1); ETV6-
RUNX1 (Pui et al., 2010; Tsunemine, 2015).The poor prognostic group includes complex 
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karyotype (>5 chromosomal abnormalities), hypodiploidy, t(4;11), KMT2A translocation, 
t(8;14), and Philadelphia chromosome positive ALL (Rowe et al., 2005, Pui et al., 2010). 
Currently, the modern genetics method including genome-wide screening techniques is 
redefining personalized care and is believed to hold promise for better-targeted therapy.  
 
 
TABLE 4: Frequencies of genetic aberrations in paediatric and adult ALL. 
Source: William's Haematology, 9th ed. 2016 
 
ABNORMALITY CHILDREN (%) ADULT (%) 
Hyperdiploidy(>50 chromosomes) 23- 29 6- 7 
Hypodiploidy (<45 chromosomes 1 2 
t(1;19)(q23;p13.3) 
[TCF3-PBX1] 
4 in whites, 12 in blacks 2- 3 
t(9;22)(q34;q11.2) [BCR-ABL1] 2- 3 25- 30 
t(4;11)(q21;q23) [MLL-AF4] 2 3- 7 
t(8;14)(q23;q32.3) 2 4 
t(12;21)(p13;q22) [ETV6-RUNX1] 20- 25 0- 3 
NOTCH1 mutations 7 15 
HOX11L2 overexpression 20 13 
LYL1 overexpression 9 15 
TAL1 overexpression 15 3 
HOX11 overexpression 7 30 
MLL-ENL fusion 2 3 
Abnormal 9p 7- 11 6- 30 
Abnormal 12p 7- 9 4- 6 
del(7p)/del(7q)/monosomy 7 4 6- 11 
+8 2 10- 12 
Intrachromosomal amplification 
of chromosome 21 (iAMP21) 
2 ? 
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TABLE 5: French American British (FAB) classification of Acute Lymphoblastic 
Leukaemia (ALL). 
Source: Oxford Handbook of clinical haematology 2nd ed. 2004 
TYPE DESCRIPTION 
L1 Lymphoblasts are small monomorphic cells with little cytoplasm and regular 
nuclei. inconspicuous nucleoli. 
L2 Lymphoblasts are heterogenous in size with much cytoplasm and fairly 
irregular nuclei. conspicuous nucleoli. 
L3 Lymphoblasts are usually large with vacuolations. 
 
 
 
 
Figure 1: FAB subtypes of acute lymphoblastic leukaemia ( A- L1; B- L2; C- L3) 
Source: Acute Leukemia– The Scientist's Perspective and Challenge. 2014 
 
 
A 
B 
C 
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TABLE 6: Immunologic classification of ALL 
Source: William's Haematology, 9th ed. 2016. 
 
SUBTYPES MARKERS CHILDREN
(%) 
ADULT 
(%) 
FEATURES 
B-cell 
precursor 
CD19+, CD22+,CD79a+, 
cIg+/–,sIgμ–, HLA-DR+ 
? ?  
Pro-B CD10- 5 11 Infants and adults age group, 
high leukocyte count, MLL 
rearrangement, pseudodiploidy 
Early pre-B CD10+ 63 52 Favorable age group (1–9 
years), low leukocyte count, 
hyperdiploidy 
(>50chromosomes) 
Pre-B CD10+/-, cIg+ 16 9 High leukocyte count, black 
race,pseudodiploidy 
Mature B cell 
(Burkitt) 
CD19+, CD22+,CD79a+, 
cIg+, sIg+ (kappa or 
lambda+) 
3 4 Male predominance, initial 
CNS leukaemia, abdominal 
masses, renal involvement 
T lineage CD7+, cCD3+    
T cell CD2+, CD1+/–, CD4+/–, 
CD8+/–,HLA-DR–, 
TdT+/– 
10 18 hyperleukocytosis, 
extramedullary disease,  
Male predominance 
Pre-T CD2–,CD1–,CD4–,CD8–
, HLA-DR+/–, TdT+ 
1 6 Extramedullary disease,   
Hyperleukocytosis, male  
Predominance, unfavourable  
prognosis            
Early T-cell 
precursor 
CD1–,CD5weak,CD8-
,CD13+,CD33+,CD11b+
,CD117+,CD65+,HLA 
DR+ 
2 ? Male predominance, age >10 
years, poor prognosis 
cCD3, cytoplasmic CD3; cIg, cytoplasmic immunoglobulin; sIg, surface immunoglobulin; TdT, 
terminal deoxynucleotidyl transferase 
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TABLE 7: WHO 2008 classification of precursor lymphoid neoplasms.  
Source: Blood and Bone marrow pathology, 2nd ed. 2011 
B lymphoblastic leukemia/lymphoma 
B lymphoblastic leukemia/lymphoma, NOS  
B lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities:  
 B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1  
 B lymphoblastic leukemia/lymphoma with t(v;11q23), MLL rearranged  
 B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)  
 B lymphoblastic leukemia/lymphoma with hyperdiploidy  
 B lymphoblastic leukemia/lymphoma with hypodiploidy  
 B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); (IL3-IGH)  
 B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)  
T lymphoblastic leukemia/lymphoma 
 
 
 
  1.2.4. Treatment of acute lymphoblastic leukaemia 
   Unlike AML the treatment schedule of ALL is quite distinct and far more complex. The 
treatment schedule is dependent on the subgroup, the prognosis and performance status of the 
patient. Unlike AML too, targeted therapy has a place in the management of ALL. The 
chemotherapy schedule consists of four phases namely, induction, consolidation, and 
maintenance. CNS prophylaxis is a phase given at intervals throughout chemotherapy.   
   The primary goal of the induction phase of chemotherapy is to bring about complete 
remission and restoration of normal haematopoiesis. The fulcrum of induction therapy 
includes vincristine, a corticosteroid (either prednisolone or dexamethasone), and L- 
asparaginase in children or an anthracycline in adults (Pui, 2006; Pieters, 2010) but with 
some modifications. In the Dana Farber cancer institute (DCFI) protocol (Moghrabi et al., 
2007), intrathecal (i.th) hydrocortisone and both intravenous (i.v) and i.th methotrexate are 
part of the constituents of the induction phase for all risk patients while the  Nordic Society of 
Paediatric Haematology and Oncology (NOPHO) ALL-2000 protocol (Vaitkeviciene et al., 
2011) has only i.th methotrexate for all risk patients. With improved induction phase and 
supportive care, complete remission rate is about 98% in children and between 85- 90% in 
adults (Fielding, 2011). After a successful induction phase, eligible patients especially the 
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high-risk group can proceed to allo- HSCT while others move on to consolidation and 
maintenance phase.  
   The continuation phase is introduced shortly after the induction phase, and it can be a 
readministration of induction phase regimen or introduction of high doses of different 
chemotherapy drugs not used during the induction phase. There is no consensus on the 
different agents to be used and the length of time it should be administered. However, most 
childhood  ALL regimen use high-dose methotrexate with or without mercaptopurine, high-
dose L- asparaginase is given for a longer period. A combination of dexamethasone, 
vincristine, l-asparaginase, with doxorubicin, and usually followed by thioguanine, 
cytarabine, and cyclophosphamide (Schrappe et al., 2013; Vrooman et al., 2013). Cranial 
irradiation is sometimes given as CNS prophylaxis. Doses as high as 5gm/m2 for 
methotrexate is sometimes given for maximal therapeutic benefit, with T cell ALL which is 
known to accumulate methotrexate polyglutamates less avidly than precursor B cell ALL 
(Galpin et al., 1997; Mikkelsen et al., 2011). The same applies to ETV6- RUNX1 which also 
accumulate significantly fewer methotrexate polyglutamates than hyperdiploidy 
abnormalities (Kager et al., 2005). The maintenance phase is an integral part of every ALL 
regimen. It is given for between 2 to 3 years depending on the sex. Studies have shown that 
girls do not benefit from the 3rd year of maintenance therapy as much as boys (Larson, 
2016), so girls usually have it for two years while boys have it for three years. Maintenance 
therapy consists of daily 6-MP, weekly methotrexate, and vincristine and a 5-day prednisone 
pulse every three months. A key component of some regimen is the reinduction therapy 
which uses the same agents as the induction phase and is given soon after the first remission 
(Hunger et al., 2011), and a second reinduction can be given anytime during maintenance 
phase to further improve outcome (Lange et al., 2002). 
   CNS prophylaxis is another vital component of ALL treatment. It can be given either as 
chemotherapy or cranial irradiation. Studies have shown that cranial irradiation is not 
necessary (Veerman et al., 2009), hence the use of systemic and intrathecal chemotherapy. 
The Systemic treatment includes high-dose methotrexate, intensive asparaginase, and 
dexamethasone (Richards et al., 2013), as well as triple intrathecal therapy with methotrexate, 
cytarabine, and hydrocortisone which has been shown to be more effective than intrathecal 
methotrexate in preventing CNS relapse (Matloub et al., 2006).  
   Allo-HSCT is usually reserved for very high risk ALL groups after the induction phase of 
chemotherapy, and this is because of unfavourable prognosis. Some studies have shown that 
high-risk patients do benefit from allo- HSCT (Oliansky et al., 2012; Gupta, 2013). A special 
36 
 
case is Philadelphia (Ph) positive ALL which had a five-year survival of between 5- 20% 
with allo- HSCT being the only chance for a cure. However, the advent of tyrosine kinase 
inhibitors had improved treatment and downplayed the efficacy of allo- HSCT after first 
remission (Schultz et al., 2009).  Allo- HSCT is still needed in some groups of high-risk 
patients (Ludwig et al., 1998). 
 
1.3 Medicinal plants 
The theory that some chemicals in plants and food might be involved in the causation and 
prevention of cancer has been around over 100 years ago. Since the ancient times, the use of 
medicines from plants and other natural materials has been the mainstay of the traditional 
medicinal system the world over. Even in modern times, the majority of the world population 
still rely on traditional medicines for their primary health care, because of the scarcity and 
cost of orthodox medicine (Ayo, 2010; Balunas 2005). Also, many herbs and plants have 
been the traditional source of raw materials for the manufacture of orthodox medicines. 
Between 1981 and 2002, about a half of the 877 new chemical entities introduced were 
natural products, semi-synthetic natural products, and their analogues or synthetic compounds 
based on natural products obtained from plants (Bhaskar and Rajalakshmi, 2010). 
 There has been renewed interest in the field of Ethnopharmacology, especially in the 
Western countries, which has partly been spurred by the epidemiological observations that 
individuals who consumed certain diets had a lower incidence of some cancers (Ambrosone, 
2004). This finding have led to scientific studies into the isolation of chemical substances 
with therapeutic properties. Many standard chemotherapeutic agents have been discovered 
from natural sources, e.g., Daunorubicin and cytarabine (Mehbub, 2014; Demain 2011).  It is 
also reported that about 25% of modern orthodox medicines have plant derivatives (Olaleye 
et al, 2006). The past decades have seen an increase in the number of people using various 
medicinal plants to treat different ailments. In the United States, about 1 in 5 people are 
reported to take herbal medicines (Bent, 2008). In South Africa, many people still use 
medicines that are derived from medicinal plants and usually sold in the informal markets 
((van Wyk et al., 2009). Some South African plants have shown anti-neoplastic activity, and 
one is still undergoing clinical trials for the management of various cancers (Chase et al., 
2017). There is a need for proper documentation of research works done in the field of 
phytomedicine so that complimentary viable alternatives available besides orthodox 
medicine, can be made known. 
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1.3.1.  Rationale for the use of natural products of  medicinal plants 
  A plant can be considered as a microcosm of a mega factory with its ability to synthesize 
numerous compounds which are beneficial to man. These compounds are also known to 
provide some form of defense against predation and some microbial infections. The ability of 
plants to synthesize so many natural compounds have puzzled biologists for some time. 
Trying to decipher the rationale has led to some theories. One of such theory is that co-
evolution within similar biospace has made interacting organisms that are near each other, 
develop certain compounds that can affect the physiological processes of other species. These 
organisms through the evolutionary process of natural selection retain those compounds that 
confer an advantage. Some of these compounds have biological effects in humans. For 
example, some phytochemicals are evolved in plants to protect against herbivores. Such 
phytochemicals have found use as emetics or muscle relaxants in man. The co-evolution 
theory also explains synergism found in some plants. The antimicrobial ability of the alkaloid 
berberine, found in such plants like  Berberis spp is enhanced by the multidrug-resistance ( 
MDR) inhibitor 5’-methoxyhydnocarpin which has no microbicidal ability of its own but to 
potentiate the antibiotic effect of berberine. While some pathogens have developed MDR 
pumps against some plants antimicrobial potentials, such plants have evolved MDR inhibitors 
as a counterstrategy to the benefit of humans (Li, 2008).  
  The other theory known as xenohormesis tries to relate chemical similarities between plants 
and animals, with the latter's lost ability to synthesize these chemicals as a result of feeding 
on plants but retains the ability to sense their chemical cues. For example, a comparative 
genomic analysis showed that about 70% of cancer-related human genes have orthologues in 
Arabidopsis thaliana (Jones et al., 2008). However, both theories have not been able to 
explain the 'ambidextral' ability of some natural compounds whose ability goes beyond a 
single target or disease. Some of these targets including monoamine oxidase A and B are 
found exclusively in animals with no homologues in plants that produce the natural 
compounds. Also in a profound sense some of these natural compounds are not drugs, but 
proto-drugs. The willow bark has long been used in traditional medicine to manage fever and 
pain. The primary effector, salicylic acid is formed from salicin which is the precursor found 
in the plant, but must first be hydrolysed in the small intestine to salicylic alcohol and further 
oxidized to salicylic acid by intestinal bacteria (Akao et al., 2002). 
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  The ability of natural compounds to bind multiple targets and synergize has been an area 
that has been unwittingly explored in traditional medicine and provided a holistic approach to 
disease management. The flavonoid curcumin (diferuloylmethane) has activity against many 
cytokines, enzymes, adhesion molecules, protein kinases and transcription factors that play a 
role in the pathology of some chronic illnesses including cardiovascular, neurodegenerative, 
metabolic, autoimmune and neoplasia (Aggarwal and Harikumar, 2009) and have been used 
to treat various ailments. Cancer as a chronic disease is also treated based on a multi-target 
approach in orthodox medicine. Many natural compounds have the potential to play a role in 
cancer combination therapy either as adjuvants, neoadjuvant or even adaptogens (Davis, 
2007). For example, the polyphenol quercetin has been shown to work synergistically with 
busulfan against human leukaemia cells (Sak, 2012). It is also known to potentiate the 
cytotoxic effects of cyclophosphamide, vincristine, and doxorubicin (Lamson, 2000). In 
summary natural compounds can play a role in cancer management and modern scientific 
approach can make it happen.  
 
1.3.2 Pelargonium species 
  The family Geraniaceae are noted for their medicinal benefits and essential oils. The genus 
Pelargonium (part of the family Geraniaceae) includes annuals and herbaceous perennials, 
shrubs and deciduous plants. There are about 250 species of the genus in the world, of which 
about 80% are found in South Africa (Lis- Balchin, 1996).Many of them have scented leaves 
which come in different sizes and shapes. The leaves can be alternate, palmately lobed or 
pinnate, and may be covered with fine hairs, sticky ones or those with a velvety texture. The 
flowers are zygomorphic with the posterior sepal fused with the pedicel to form a 
hypanthium. The flowers come in different colours ranging from white to burgundy. 
  The Pelargonium species are used widely by traditional healers in South Africa including 
the Sothos, Xhosas, Khoi-Sans, and Zulus, for its curative and palliative effects in the 
treatment of diarrhoea, dysentery, fever, respiratory tract infections, liver complaints, 
wounds, gastroenteritis, haemorrhage, kidney and bladder disorders (Van Wyk et al, 2009). 
Both the rhizome and herb have been used to treat malaria, inflammation, abdominal and 
uterine disorders (Lis- Balchin, 1996). The root extracts have been shown to have 
antibacterial, antifungal and antitubercular activity; and in South Africa, traditionalists use it 
for the treatment of coughs and tuberculosis (Mativandlela et al., 2006). Ethanol extracts of 
the roots of two species of Pelargonium (P. sidoides and P. reniforme) have been used in 
Germany since 1980s as an herbal medicine for the management of acute and chronic 
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respiratory infections (EMA, 2013). An assessment report of the European medicines agency 
(EMEA) showed that herbal extracts of P. sidoides and P. reniforme are widely marketed in 
several European countries and have proven pharmacological and clinical efficacy for 
symptoms of respiratory infections (EMA, 2013). But the medicinal use of pelargonium 
transcends respiratory infections; Pelargonium sublignosum has been shown to have 
significant antimicrobial activity against the Gram-positive bacteria (S. aureus and Bacillus 
cereus) and Gram-negative bacterium K. pneumoniae. P.quercetorum induce apoptosis 
without the cleavage of poly (adenosine diphosphate-ribose) polymerase (PARP) or 
cytokeratin 18 in vitro (Aztopal, 2016) and also induce apoptosis in MCF-7 cell lines (Ali et 
al., 2017). P. sidoides have been shown to induce cell cycle arrest and apoptosis in leukaemia 
cell lines (Perreira et al., 2016). 
 Pelargonium spp. are known to be a rich source of various phytochemicals including 
monoterpenes, sesquiterpenes, coumarins, tannins, phenolic acids, cinnamic acids, flavones, 
flavonoids and flavonols derivatives. Extensive work has been done on P. graveolens, P. 
sidoides, P. reniforme and P. radula, and they have found use in different industries.  
 
1.3.3 Opuntia species 
   Opuntia spp. represent one of the most diverse and distributed genera of plants. It is found 
on all continents except Antarctica (CABI,2017). It has its greatest degree of diversity in 
Mexico, where it probably originated, with various degree of domestication observed (Reyes- 
Aguero and Aguirre Rivera, 2011). It has since been introduced all over the world and can be 
found in temperate, subtropical and tropical regions. It was introduced into South Africa in 
the 1700s where it is regarded as a weed and has been actively controlled using biological 
means. It is a member of the family Cactaceae, subfamily Opuntioideae, tribe Opuntieae. 
About 1500 species of cactus are in the genus Opuntia. The plants (especially Opuntia ficus 
indica) are known as health-promoting foods with their sweet, edible fruits and young 
cladodes eaten as a vegetable in salads;  and also some medicinal properties (Santo-Diaz et 
al., 2017).  
   Opuntia spp. extracts have been used for several centuries in the management of different 
ailments which include chronic and inflammatory conditions like diabetes, rheumatism, 
asthma, hypercholesterolaemia, and hypertension (Osuna- Martinez et al., 2014). Recent 
scientific studies have further increased interests in these plants. For example, studies done 
by Budinska and colleagues (2001) observed that patients diagnosed with familial 
heterozygous hypercholesterolaemia had much-lower LDL cholesterol plasma and urine 
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levels of 8-epi-prostaglandin F2α with regular consumption of Opuntia robusta fruits. In a 
similar experiment, mice fed with methanolic extract of Opuntia joconostle seeds showed a 
significantly lowered plasma LDL cholesterol and triglycerides levels compared to animals 
fed with placebo (Osorio-Esquivel et al., 2012). Although it has not been reported to be used 
as an antineoplastic agent in traditional medicine, scientific studies carried out showed 
Opuntia spp. has some activity on cancer. Work done by Kim and colleagues revealed that 
extracts from Opuntia humifusa cladodes could cause apoptosis in MCF-7 cells and human 
colonSW-480 cells (Kim et al., 2015). Water partitioned fractions of stem and fruits of 
Opuntia humifusa has also been reported to inhibit the growth of U87MG glioblastoma cells 
with increased production of reactive oxygen species in the cells (Hahm et al., 2010). Opuntia 
is also known to have antibacterial and antifungal properties. Essential oils from Opuntia 
stricta were shown to inhibit the growth of Bacillus cereus and Candida albicans at very low 
concentrations (Moosazadeh et al., 2014). 
 
1.3.4 Safety evaluation of medicinal plants 
   While medicinal plants have been in use for centuries by traditional practitioners, for the 
management of various ailments, dosage and preparation have been concerns surrounding 
their use. Nephropathy and hepatotoxicity are usually the two most common toxicity. A 
particular case was the use of the Chinese herb Aristolochia fangchi for weight loss by some 
patients in Belgium. Forty-three of these patients developed the end-stage renal disease, while 
thirty-nine had their kidneys surgically removed. Eighteen of these patients were later found 
to have a urothelial carcinoma, which was shown to be as a result of the formation of DNA 
adducts from aristolochic acid in the herb (Nortier et al., 2000). Some herbal products also 
have contaminants that can have undesired effects. A study that examined the makeup of 
about 260 Asian patent medicines discovered that about 25% had increased levels of heavy 
metals (Ko, 1998). 
   Herbs and drug interactions are also known to be problematic in disease management. 
While some can be beneficial others are antagonistic. Genistein, an isoflavone is known to 
reduce the tumouricidal efficacy of tamoxifen in estrogen-dependent breast carcinoma cells 
(Ju et al., 2002) and curcumin has been shown to enhance vinorelbine mediated apoptosis in 
non-small cell lung carcinoma cells (Sen et al., 2005). It is therefore important that 
toxicological screening is done on herbal products to forestall some unpleasant effects. 
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1.3.5 The choice of Opuntia stricta and Pelargonium inquinans  
   The choice of Opuntia stricta and Pelargonium inquinans for this study (FIG 2 a,b) is 
based on   
(i.) a review of studies carried out on other members of the plant's family which 
showed antineoplastic activities (Saraswathi et al., 2011; Santos- Diaz et al., 
2017);  
(ii.) a review of the literature that indicated these plants had not been studied with 
regard to their antineoplastic activities especially in the Eastern Cape of South 
Africa; and  
(iii.) the availability of the plant materials.  
                                                                                  
 
FIG. 2a Opuntia stricta                                 FIG. 2b Pelargonium inquinans 
 
1.4 Statement of research problem  
 Acute lymphoblastic leukaemia is the most common paediatric cancer, and the mainstay of 
management is combination chemotherapy and haematopoietic stem cell transplant (HSCT). 
Although therapy has improved, and about 80% of patients are cured with intensive 
combination chemotherapy, about 20% of paediatric patients and 40-50% of adults do relapse 
(Kaatsch, 2010). Cure rates of relapse are approximately between 25-40% in children and 
about 10% in adults (Duval,  2010). Relapse is thus a great concern. AML has a worse 
clinical picture of practically all patients who achieve complete remission will relapse 
without further treatment (Baron, 2012). Post-remission maintenance chemotherapy with or 
without HSCT is vital to preclude a relapse. However, HSCT has a mortality rate of about 
10% to 25% (Baron, 2012). Over four decades the mainstay of treatment has not changed 
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therefore the development of new lead compounds is necessitated for the treatment and 
prevention of leukaemia. 
 
1.5 Aims and objectives  
The main objective of this study is to evaluate the anti-neoplastic properties of extracts of 
Opuntia stricta and Pelargonium inquinans in vitro using acute leukemia cell lines. 
Specific objectives 
1. To evaluate the proapoptotic activity and cell cycle arrest of Opuntia stricta and 
Pelargonium inquinans extracts on acute leukemia cell lines. 
2. To evaluate the cytotoxicity of Opuntia stricta and Pelargonium inquinans extracts on 
acute leukemia cell lines. 
3. To evaluate the antioxidant, anti-inflammatory, antibacterial and phytochemical properties 
of the two plants. 
4. To identify volatile bioactive compounds from the essential oil of these plants using  
GC/MS.  
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CHAPTER TWO 
2.1 Introduction 
2.1.1 Oxidative stress 
   Oxidative stress(OS) can be defined as a yin-yang relationship between free radicals/ 
reactive oxygen species (ROS) generated as a result of some cellular (re)actions and 
antioxidants (constitutive or endogenously) produced to either mollify or abrogate their 
effects. Free radicals can be said to be molecules that contain one or more unpaired valence, 
making them highly reactive. OS  is important in health and disease, especially chronic 
diseases. It has both beneficial and deleterious effects. For example,  OS has been shown to 
induce cell death, and also enhance antimicrobial phagocytosis by the release of reactive 
oxygen species through the immune cells (Valko et al., 2007). They do this by acting as stress 
signals for certain signaling pathways and intermediates that modulate physiological 
processes (Finkel and Holbrook, 2000). However, excessive production of ROS without a 
counterbalance by the innate antioxidant system will cause the cell to be stressed. OS is 
involved in many degenerative diseases and inflammatory conditions like atherosclerosis, 
Parkinson's disease and cancer (Udensi and Tchounwu, 2014). Cancer therapies such as 
chemotherapy and radiation also generate ROS, which leads to an OS environment which can 
either be beneficial or harmful. 
   The effect of OS can be either acute or chronic. For chronic OS, a small amount of 
oxidative damage can persist during physiological functioning of the cell and lead to 
disruption of essential cellular functions and a premorbid state of carcinogenesis through the 
promotion of cell survival (Maraldi et al., 2009), cellular proliferation (Arnold et al., 2007), 
metastasis (Wu et al., 2008) and even drug resistance (Trachootham et al., 2009). ROS plays 
a role in many cancers including haematological cancers like the myeloid leukemias (Sallmyr 
et al., 2008), and ALL (Battisti et al., 2008). AML relapse has also been strongly associated 
with increased markers of oxidative stress, implying that ROS can be a pivotal factor in AML 
progression (Zhou et al., 2010). Thus, the regulation of OS is important in cancer growth and 
management, and so a better understanding of it will aid in both the definitive and supportive 
care of various types of leukaemia.  
   ROS are produced as a result of endogenous and exogenous factors. The endogenous 
factors include cellular metabolites from mitochondria- catalyzed electron transport reactions, 
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and activities of leukocytes such neutrophils, eosinophil, monocytes and cellular organelle 
peroxisomes during inflammation (the enzymes involved in generating ROS are found in 
these cells and organelles, e.g., macrophages can trigger an increase in ROS during an 
inflammatory response). Exogenous factors include irradiation, various drugs, and xenobiotic 
agents. ROS include superoxide anion (O2
-), hydrogen peroxide (H2O2), hydroxyl 
radical(HO•), and singlet oxygen (1O2). Superoxide anion can also combine with nitrous 
oxide (NO) to form reactive nitrogen species (RNS). They can cause nitrosative stress from 
its various species which include peroxynitrite (ONOO−), nitrosoperoxycarbonate 
(ONOOCO2
−), nitrogen dioxide (•NO2), and dinitrogen trioxide (N2O3).  
   The body has a defense network of antioxidants, which include the tripeptide glutathione 
and enzymes like superoxide dismutase and catalase, to nullify the harmful effects of free 
radicals on cells. These antioxidants are endogenous and are produced mainly in the 
mitochondria. Others include alpha lipoic acid (ALA), Coenzyme Q10 (CoQ10), glutathione 
peroxidase (Gpx), ferritin, uric acid, bilirubin, metallothionein, L-carnitine and melatonin 
(Rizzo et al., 2010). Where the endogenous antioxidants do not suffice, the exogenous ones 
which are acquired from foods can help out. These include vitamins such as E and  C which 
are involved in lipid peroxidation and enhancement of OS cells respectively (Rizvi et al., 
2014; Montencinos et al., 2007).  Other important exogenous antioxidants found in plants 
include phenolic compounds (phenolic acids, flavonoids, quinones, coumarins, lignans, 
stilbenes, tannins, etc.), nitrogen compounds (alkaloids, amines, betalains).  
   In a study carried out by Pujari et al. (2011), the overall mean erythrocyte SOD level was 
found to be low in leukaemia patients when compared to normal controls, which was more 
prominent in acute leukaemias. Another study revealed that a higher level of DNA base 
lesions and low antioxidant levels were found in children with ALL when compared to 
disease-free children (Senturker et al., 1997), giving insights into a link between low levels of 
endogenous antioxidants, increased ROS and carcinogenesis. Low levels of SOD have also 
been reported in other haematological cancers as well as in solid tumours (Magolova et al., 
1999; Sharma et al., 2009). These findings suggest a probable role for antioxidants in cancer 
prevention. The apoptotic effect of  Cellfood™, a nutritional supplement containing 
deuterium sulfate, minerals, amino acids, and enzymes with well documented antioxidant 
properties, whose organic and inorganic components are extracted from the red 
algae Lithothamnion calcareum,  were evaluated on three leukemic cell lines including 
Jurkat, U937, and K562 cells. It was found to induce apoptosis, downregulate HIF-1α and 
GLUT-1 expression as well as reduce lactate dehydrogenase activity (Catalani et al., 2013). 
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Due to their actions, exogenous antioxidants such as vitamins are increasingly seen as viable 
therapies in leukaemia management. According to Al - Tonbary et al. (2009), a group of 
children newly diagnosed with ALL were given Vitamin E and N- acetylcysteine as adjuvant 
antioxidant therapy along with standard chemotherapy, while another group was only given 
standard chemotherapy. The group given adjuvant antioxidant therapy recorded lower levels 
of malondialdehyde, with an increased level of glutathione peroxidase along with the 
decreased occurrence of haematological complications and toxic hepatitis. The Ten-Eleven 
Translocation-2 (TET2) enzyme activity is known to be enhanced in the presence of vitamin 
C (TET2 mutation is common in AML). Very recently, vitamin C was reported to induce 
differentiation and death of AML cells in both in vitro and orthotopically transplanted mice 
(Cimino et al., 2017; Agathocleous et al., 2017 ). Various studies have shown the promise of 
using vitamin D and its analogs in the management of AML and myelodysplastic syndromes 
(Harrison, 2012). In contrast, isothiocyanates up-regulate ROS in killing some 
haematological cancer cells (Trachootham et al., 2008). 
   With such documented works of the efficacy of some food and medicinal plant products as 
viable options in the management of leukaemia, this section seeks to evaluate the 
phytochemical, vitamin content as well as the antioxidant potential of two medicinal plants 
Opuntia stricta and Pelargonium inquinans.   
 
MATERIALS AND METHODS 
2.2.1 Preparation of extracts 
   The cladodes of Opuntia stricta and the leaves of Pelargonium inquinans were collected 
from the University of Fort Hart Campus at Alice. The plants were authenticated at the 
Albany herbarium in Rhodes University, Grahamstown. The cladodes and leaves were 
collected and divided into two parts. 300g of fresh cladodes and leaves each were separately 
chopped and extracted in 1 litre of water, ethanol, and acetone respectively on a shaker for 
48hours. The remaining cladodes and leaves were dried in the oven at 40OC and later 
pulverized. About 300g of the pulverized samples were also extracted with the same type and 
volume of separate solvents (water, ethanol, and acetone) on a shaker for 48hours. Both the 
fresh and the dry extracts were filtered with a funnel and Whatman filter paper. While the 
ethanol and acetone extracts of both the fresh and dried samples were concentrated at 78oC 
and 56oC, respectively using a rotary evaporator, the water extracts of both samples were 
frozen at -40oC with an acetone chiller, then freeze-dried. The extracts were stored away in a 
refrigerator at 4oC.  
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Phytochemical analyses 
2.2.2 Estimation of total phenol content 
   The total phenol was estimated spectrophotometrically by using the Folin-Ciocalteu assay 
method (Tambe and Bhambar, 2014). About 0.5ml of the extract was mixed with 2.5ml of 
10% Folin-Ciocalteu reagent in tubes, vortexed for about 30s and allowed to stand for 10 min 
at 25oC.  After which 2 ml of 7.5% anhydrous sodium carbonate was added and vortexed 
again for another 30s. The tubes were incubated in a water bath at 40oC for 30min for colour 
development, and absorbance read at 765nm using a spectrophotometer. Gallic acid standards 
were prepared in the same manner as the extracts as described earlier. The total phenolic 
content was then expressed as mg/g gallic acid (GAE/gm) equivalent using the following 
equation based on the calibration curve: Y= 0.0052x, R2 = 0.9846. 
  
2.2.3 Estimation of total flavonoid content 
   The total flavonoid content was estimated spectrophotometrically by using the aluminum 
chloride colorimetric assay(Tambe and Bhambar, 2014). The reaction mixture was made up 
of 0.5ml of the plant extract, 2ml of distilled water in a tube and 0.15 ml of 5% sodium 
nitrite. The mixture was allowed to stand for 5 min at room temperature after which 0.15 ml 
of 10% aluminum chloride was added to the solution and allowed to incubate for another 5 
min. After incubation, 1ml of 4% sodium hydroxide was added and the solution made up to 5 
ml with distilled water. The solution was then vortexed and incubated for 15 min to observe a 
colour change. The absorbance was measured at 420nm. The total flavonoid content was 
calculated as mg/g quercetin equivalent using the following equation from the calibration 
curve: Y= 0.0029x, R2 = 0.997.  
 
2.2.4 Estimation of total flavonol content 
   The total flavonol content was estimated using the method described by Wintola and 
Afolayan (2011). 2 ml of the plant extract was added to 2 ml of 10% aluminum chloride 
prepared in ethanol. To this 3 ml of 5%, sodium acetate was added and then incubated at 
20oC for 21/2 hours. The absorbance was measured at 440nm with a spectrophotometer. Total 
flavonol content was expressed as mg/g of quercetin equivalent derived from the following 
calibration curve: Y= 0.0107x, R2= 0.9928. 
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2.2.5 Estimation of proanthocyanidin 
   The total proanthocyanidins were estimated using the method described by Caceres- Mella 
et al. (2013) by mixing 0.5 ml of the prepared plant extract with 3 ml of  4% vanillin-
methanol. 1.5 ml of hydrochloric acid was added to the solution and vortexed. The mixture 
was left to stand for 15 min at room temperature. The absorbance was then read at 500 nm 
using a spectrophotometer. Total proanthocyanidins content was calculated as mg/g of 
catechin equivalents using the equation derived from the calibration curve: Y= 0.0025x, R2= 
0.9923.  
 
2.2.6 Estimation of tannin content 
   The total tannin content was estimated using the  Folin - Ciocalteu method (Tambe and 
Bhambar, 2014). 7.5 ml of distilled water was added to a tube containing 0.1ml of the plant 
extract. 0.5 ml of 10% Folin-Ciocalteuphenol reagent and 1 ml of 35 % Na2CO3 solution was 
then added. The whole solution was made up to 10 ml with distilled water. The mixture was 
vortexed and kept at room temperature for 30 min. The absorbance was read at 725 nm using 
a spectrophotometer. A prepared set of standards of gallic acid was prepared in the same 
manner as the extracts as described earlier. The total tannin content was expressed as mg/g 
GAE  using the following equation derived from the calibration curve: Y= 0.0122x, R2= 
0.9838.  
 
2.2.7 Estimation of alkaloids content 
   The total alkaloid content was estimated using the method described by Unuofin et al. 
(2017). 5 g of the pulverized plant was immersed in 200 mL of 10% acetic acid in ethanol. 
The mixture was allowed to stand for 4hr at room temperature (25oC). It was subsequently 
filtered, and the filtrate was concentrated using a water bath at 55oC to a quarter of its original 
volume.  Concentrated ammonium hydroxide was added in single drops until completion of 
the precipitation process. The solution was then washed with dilute ammonium hydroxide 
and filtered again. The residue obtained was first dried at room temperature (25oC) in an oven  
and then weighed. The alkaloid content was calculated using the equation: 
 
 % Alkaloid = Weight of precipitate   X 100 
                       Weight of original sample  
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2.2.8 Estimation of saponin 
   The saponin content was determined according to the method described by Omoruyi et al. 
(2012) with some modifications. 5 g of the pulverized plant was added to 20 ml of 20% 
ethanol and extracted on a shaker for 30 min. The plant sample was heated over a water bath 
at 55oC for four h. The mixture was filtered, and the residue was re-extracted again with 20 
ml of 20% aqueous ethanol. The filtrate was then reduced to 40 ml over a water bath at 90oC. 
The concentrate was transferred into a 250 ml separatory funnel, and extracted twice with 20 
ml diethyl ether. The ether layer was discarded while purification process was repeated. Sixty 
milliliters (60 ml) of n-butanol was added, and the extract was washed twice with 10 ml of 
5% aqueous sodium chloride. The remaining solution was heated over a water bath and 
evaporated to dryness to a constant at 40oC. The saponin content was calculated using the 
following equation:   
 
  % Saponins contents = Weight of residue × 100   
                                       Weight of sample 
 
2.2.9 Estimation of phytate content 
   The total phytate content was estimated using the method described by Unuofin et al. 
(2017). 2 g  of the pulverized plant was soaked into a conical flask with 50 ml of 2% 
hydrochloric acid for 3h and afterward filtered. 25 ml of the filtrate was taken, and 5 ml of 
0.3% ammonium thiocyanate solution was added. 53.5 ml of distilled water was also added to 
achieve the desired acidity. Then 0.05 M of iron III chloride was titrated into it until a reddish 
brown colour persists for 5 min. Phytate content was calculated as:  
Phytate (%) = titre value × 0.001 95 × 1.19 × 100. 
 
2.2.10 Estimation of oxalate content 
   The total phytate content was estimated using the method described by Unuofin et al. 
(2017). 1g of the pulverized plant was put into a conical flask with 75ml of 3M of H2SO4 
added to it and stirred with a magnetic stirrer for about 1hr. The solution was filtered, and 
25ml of the filtrate was heated to about 80oC. While around this temperature 0.05M of 
KMnO4 was titrated against the hot aliquot until an extremely faint pale pink colour persists 
for 15-30 s. The oxalate content was calculated by taking  1mL of 0.05 M of KMnO4 as 
equivalent to 2.2 mg oxalate.  
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Antioxidant assays 
2.2.11 DPPH radical scavenging assay  
   DPPH radical scavenging activity of the plant extracts was determined according to the 
method described by Wintola and Afolayan (2012) with some modifications. A preparation 
of 1 ml of 0.135 mM DPPH in methanol was mixed with 1ml of various concentrations (0.2 – 
1.0 mg/ml) of the plant extracts, vitamin C, and gallic acid. The mixture was left in the dark 
at room temperature for 30 min after being vortexed. The absorbance of the mixture was then 
measured spectrophotometrically at 517 nm. Both vitamin C and gallic acid were used as 
standards.The DPPH radical scavenging activity was calculated from the equation:  
 
DPPH radical scavenging activity = {(Abs control – Abs sample)}/ (Abs control} × 100 
 
 where Abs control was the absorbance of DPPH radical + methanol; Abs sample was the 
absorbance of DPPH radical + sample extract or standards (Vitamin C and gallic acid). 
   
2.2.12 Ferric reducing antioxidant power assay  
  The reducing power of the plant extracts was determined according to the method described 
by (Vijayalakshmi and Ruckmani,(2016) with some modifications. 1ml of the extract 
prepared in distilled water, Vitamin C or gallic acid (0.2 - 1.0 mg/ml) were mixed separately 
with 2.5 ml of phosphate buffer (0.2M, pH 6.6) and 2.5 ml of 1% potassium ferricyanide. The 
resulting mixture was vortexed and incubated at 50oC for 20 min. After incubation, 2.5 ml of 
10% trichloroacetic acid (TCA) was added to stop the reaction, and then centrifuged at 3000 
rpm for 10 min. 2.5 ml of the solution representing the upper layer was mixed with  2.5 ml of 
distilled water, and 0.5 ml of 0.1% ferrous chloride were mixed and incubated for 10 min. 
The absorbance was then measured at 700 nm on a spectrophotometer. 
 
2.2.13 Nitric oxide scavenging activity  
   Nitric oxide scavenging activity was determined according to the method described by 
Boora et al. (2014) with some modifications.  An aliquot of 2 ml of 10 mM sodium 
nitroprusside was prepared in 0.5 ml phosphate buffer saline (pH 7.4) and  mixed with 0.5 ml 
of either plant extracts, vitamin C or gallic acid,  at various concentrations (0.2-1.0 mg/ml). 
The mixture was incubated at 25oC for 150 min. After incubation, 0.5 ml of Griess reagent 
(1.0 ml of 0.33% sulfanilic acid reagent prepared in 20% glacial acetic acid at room 
temperature for 5 min with 1 ml of naphthylethylenediamine dichloride) was added to an 
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equal volume of the incubated solution. The mixture was incubated for another 30 min at 
room temperature, and the absorbance was then measured at 540 nm. The amount of nitric 
oxide radical inhibited by the extracts was calculated using the following equation:  
NO radical scavenging activity = {(Abs control – Abs sample)}/ (Abs control } × 100  
 
where Abs control was the absorbance of NO radical + methanol; Abs sample was the 
absorbance of NO radical + sample extract or standards (Vitamin C and gallic acid). 
   
 
2.2.14 Hydrogen peroxide radical scavenging assay  
   Hydrogen peroxide scavenging activity of the extracts was determined using the method 
described by Oyedemi et al. (2010). 4 ml of plant extract, vitamin C or gallic acid was 
prepared in distilled water at different concentrations (0.2-1.0 mg/ml) and mixed with 0.6 ml 
of 4 mM Hydrogen peroxide (H2O2)  solution prepared in phosphate buffer (0.1 M, pH 7.4). 
The solution was incubated for 10 min at room temperature. The absorbance of the solution 
was then measured at 230 nm. The amount of hydrogen peroxide radical inhibited by the 
extract was calculated using the following equation:  
H2O2 radical scavenging activity = {(Abs control – Abs sample)}/ (Abs control} × 100  
 
where Abs control was the absorbance of H2O2 radical + methanol; Abs sample was the 
absorbance of the H2O2 radical + sample extract or standard (Vitamin C and gallic acid).  
 
2.2.15 Phosphomolybdenum antioxidant assay 
    The total antioxidant capacity was determined by the method described by Ahmed et al. 
(2015) with some modifications. 0.5 ml of plant extracts, vitamin C and gallic acid prepared 
in varying concentrations (0.1-0.5 mg/ml) were mixed with three ml of distilled water and 
1ml of phosphomolybdate reagent in test tubes. The solutions were then incubated at 95oC for 
90 mins. After incubation, the tubes were normalized to room temperature for about 30mins. 
The absorbance of the solution was then measured at 695 nm. The amount of hydrogen 
peroxide radical inhibited by the extract was calculated using the following equation:  
phosphomolybdate antioxidant activity =  
{(Abs control – Abs sample)}/ (Abs control} × 100 
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where Abs control was the absorbance of phosphomolybdate reagent + methanol; Abs sample 
was the absorbance of phosphomolybdate reagent + sample extract or standard (Vitamin C 
and gallic acid).  
 
 
Vitamins estimation 
2.2.16 Vitamin A estimation 
   Vitamin A estimation was done by the method described by Onyesife et al. (2014). 20ml of 
petroleum ether was added to 1g of pulverized plant and put on a shaker for about 30mins. 
The petroleum ether was decanted and evaporated to dryness. 0.2ml of chloroform-acetic 
anhydride (1:1 v/v) was added to the residue. Later on 2ml of trichloroacetic acid- chloroform 
(1:1 v/v) was added. The absorbance of the solution was then measured at 620 nm. The 
vitamin A standard was also prepared in the same way at varying concentrations, and a 
standard curve plotted. Results were expressed in mg/100g and calculated from the following 
equation based on the calibration curve: Y= 0.001x + 0.0018. R2=  0.9922.  
 
2.2.17 Vitamin C estimation 
   Vitamin C estimation was done by the method described by Igwe and Okwu (2013) A 1g of 
the pulverised plant was put in 20ml of 0.4% oxalic acid. It was then filtered using a 
Whatman filter paper, and 1ml of the filtrate was mixed with 9ml of indophenol reagent. The 
absorbance of the solution was measured at 520nm. The vitamin C standard was also 
prepared in the same way at varying concentrations, and a standard curve plotted. Results 
were expressed in mg/100g using the following equation based on the calibration curve: Y= 
0.67x + 0.0824. R2=  0.9714.   
 
 
 
2.2.18 Vitamin E estimation 
   Vitamin E estimation was done by the method described by Onyesife et al. (2014). 20ml of 
ethanol was added to 0.5g of the pulverized sample and then left on a shaker for 20mins. It 
was then filtered. 1ml of the filtrate was then mixed with 1ml of 0.2% of ferric acid in ethanol 
and 1ml of 0.5% α-α-dipyridine. The solution was made up to 5mls with distilled water. The 
absorbance of the solution was read at 520 nm. The vitamin E standard was also prepared in 
the same way at varying concentrations, and a standard curve plotted.  Results were 
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expressed in mg/100g using the following equation based on the calibration curve: Y= 
0.0086x + 0.0216. R2=  0.99. 
 
2.2.19 Statistical analysis 
Data obtained were presented as means ± SD. All experiments were done in triplicates. The 
One way analysis of variance (ANOVA) and the Tukey test were used to determine the 
differences among the means of the various samples. P values < 0.05 were regarded to be 
significant. 
 
2.3 RESULTS AND DISCUSSION 
2.3.1 Phytochemical analysis of Opuntia stricta 
   Opuntia spp. are known to be composed of various phytochemicals including phenols, 
flavonoids,  tannins, saponins, proanthocyanidins, etc. Different parts of these plants are 
known to possess these specific compounds in varying amounts. Phytochemical analysis of 
Opuntia stricta extracts (acetone, aqueous, ethanol) showed that it possesses some of these 
compounds albeit in varying amounts (Fig 3). Many of these phytochemicals from Opuntia 
stricta are beneficial to health including their antioxidant and radical scavenging activities as 
well as their anti-inflammatory properties (El-Mostafa et al.,2014).  
    The total phenolic content of the different solvent extracts of Opuntia stricta cladodes 
showed variable yields in this study (Fig.3). The yields were 101.81mg/g, 82.54mg/g, 
54.98mg of GAE equivalent per gram of dried extract of acetone, aqueous and ethanol 
respectively.  The acetone extract of the Opuntia stricta cladodes yielded significantly higher 
(P < 0.05) phenolic contents than the aqueous and ethanol extract.The aqueous extract was 
also significantly higher (P< 0.05) than the ethanol extract. Phenolic compounds have been 
shown to exhibit various biological activities in different diseases especially chronic diseases 
like cardiovascular ailments and cancer (Pandey and Rizvi, 2009). Gallic acid (3,4,5 
triphydroxyl- benzoic acid) is also known to have good cytotoxic activity against some 
cancer cells (You and Park, 2009). 
   The total flavonoid content was low compared to the total phenolic content. The ethanol 
extract of Opuntia stricta exhibited a higher yield of 57.93mg of quercetin equivalent per 
gram of dried extract. The acetone and aqueous yields were 20.37, 17.01 mg of quercetin 
equivalent per gram of dried extract respectively. The ethanol extract showed significantly 
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higher (P< 0.05) yields than the aqueous or acetone extract. Flavonoids have been studied 
extensively, and are known to have antioxidative, anti-inflammatory and antineoplastic 
effects (Aggarwal and Harikumar, 2008). The cladodes of some cactus plants have been 
shown to produce some high amounts of flavonoids and flavonoid-like compounds, including 
isoquercetin and nicotiflorin (El-Mostafa et al., 2014). Nicotiflorin has been shown to have 
anti-inflammatory and neuroprotective properties against cerebral ischaemia (Li et al., 2006), 
while isoquercetin is currently under clinical investigation as an antithrombotic in certain 
cancer patients (NCT02195232). 
 
Figure 3: Phytochemical constituents identified in the various extracts of Opuntia stricta. 
Values are expressed as mean ± standard deviation (SD) of three separate determinations (n = 
3) 
 
   Flavonols were also present in the acetone and aqueous extracts. The acetone extract had a 
higher flavonol content at 16.11mg of quercetin equivalent per gram of dried extract 
compared to aqueous extract of 10.84mg of quercetin equivalent per gram of dried extract. 
The ethanol extract was negligible at 1.9mg of quercetin equivalent per gram of dried extract. 
The acetone and the aqueous extracts showed significantly higher (P<0.05) yields when 
compared to the ethanol extract.Flavonols are widely distributed in foods and fruits such as 
apples, beans, and berries. They are a subclass of flavonoids, and they possess good anti-
oxidative and anti-inflammatory properties (Antunes-Ricardo et al., 2015). Kaempferol has 
been shown to induce apoptosis in MCF-7 breast cancer cell lines (Liao et al., 2016). 
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   Proanthocyanidins were also found in the plant extracts in this study, though in low 
amounts. The acetone extract of Opuntia stricta cladodes gave the highest yield at 10.4mg of 
catechin equivalent per gram of dried extract. The aqueous and ethanol extracts were 9.2 and 
6.4mg of catechin equivalent per gram of dried extract respectively. Proanthocyanidin is 
ubiquitous in plants and has been found to be powerful antioxidants- their antioxidant activity 
is reported to be 20 times greater than vitamin E and 50 times greater than vitamin C (Shi et 
al., 2003). A few of the compounds are also known to exhibit cytotoxicity towards cancer 
cells (Cvorovic et al., 2010).  
   Tannin content of the cladodes of Opuntia stricta was low in this study. They were 
18.38,5.84 and 8.32mg of GAE equivalent per gram of dried extract in acetone, aqueous and 
ethanol extracts respectively. The tannin content showed no significant differences (P > 0.05) 
in the three extracts. Tannins are known to be anti-nutritive, but have been shown to have 
antioxidative properties especially lipid peroxidation; their anticarcinogenic and 
antimutagenic properties are believed to be as a result of these antioxidative properties 
(Chung et al., 1998). To the best of my knowledge, tannin contents have not been reported in 
the cladodes of Opuntia stricta, though Kunyanga et al. (2014) reported the tannin contents 
of the Opuntia stricta fruits.  
  Alkaloids like tannins are also anti-nutrient. However, some of them are important with 
known pharmacological actions. Their pharmacological activities range from antimicrobial to 
antihypertensive and anticarcinogenic. They are also known to affect the nervous system. 
Thus, are used to manage some conditions that involve the nerves. In this respect, they can 
act as poisons. The drugs vincristine and vinblastine are alkaloids derived from the plant 
Catharanthus roseus and currently used in the management of various leukemias 
(Schiemegelow et al., 2010). The alkaloid content from the pulverized sample of Opuntia 
stricta was 0.32% which is comparable to the alkaloid content of Catharanthus roseus (Adel 
et al., 2012). 
   Saponins are glycosides with triterpenoid or spirostane aglycones that have been reported to 
exert different pharmacological actions such as anti-inflammatory, immunoregulatory and 
also antineoplastic (Xu et al., 2016). The saponin content from the pulverized sample of 
Opuntia stricta was relatively high compared to the control (Table 8), which can easily be 
explained since carbohydrates are the second highest constituents found in the cladodes of 
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Opuntia after water (Santo Diaz et al., 2017). The presence of saponins in the plant can 
perhaps explain its anti-inflammatory properties in this study. 
  Phytate is also known to be anti-nutritive but has been discovered to have some health 
benefits. Some of their pharmacological activity includes lowering of blood sugar and lipids, 
antioxidants, and prevention of nephrolithiasis (Schlemmer et al., 2009).The phytate content 
of Opuntia stricta was low in this study in comparison to other phytochemicals (Table 8).  
               
Table 8: Anti-nutrient composition of Opuntia stricta cladodes 
 
Bioactive compound Content (%) 
Saponin  93.8 ± 3.43 
Alkaloid  0.32 ± 0.02 
Phytate  0.37 ± 0 
  
 
2.3.2 Phytochemical analysis of  Pelargonium inquinans 
   The plants that belongs to the Pelargonium spp are noted for their medicinal benefits in 
herbal medicine, as a result of its rich composition of phytochemicals.These phytochemicals 
include phenolics, flavonoids, tannins, and coumarins. They are known to possess some 
health benefits ranging from antioxidation to antimicrobial as well as cell cytotoxicity 
(Saraswathi et al., 2011). Their essential oils have found use in the cosmetic industry and also 
for aromatherapy. Umckaloabo, a herbal extract from the plant P. sidoides is used in the 
treatment of acute respiratory tract infections (Kolodziej, 2007). The Pelargonium spp. is 
thus an interesting plant genus to study. For P. inquinans, a search of the literature did not 
reveal anything about its chemical composition.  
   In this study, the total phenolic content (Fig. 4) in each of the leaf extract showed varying 
yields with ethanolic extract showing the highest yield at 385.25mg of GAE per gram of 
dried extract, followed by the acetone extract at 299mg and water at 170.5mg of GAE per 
gram of dried extract. The ethanol extract was significantly higher (P<0.05) than the acetone 
and aqueous extract.  These results were higher than the different solvents of the root extract 
of P. endlicheranum reported by Karatoprak et al. (2017); ethyl acetate extract 305mg of 
GAE per gram of dried extract and the leaf extract of P. graveolens; ethyl acetate extract 
73 
 
145.25 mg GAE/g (Hsouna and Hamdi, 2012). Phenols have been reported to have many 
biological activities including antioxidative and anti-neoplastic activities (Jafari et al., 2014). 
The presence of high phenol content may indicate that P. inquinans have high antioxidant 
activity. 
 
Figure 4: Phytochemical constituents identified in the various extracts of Pelargonium 
inquinans. Values are expressed as mean ± standard deviation (SD) of three separate 
determinations (n = 3) 
 
   The total flavonoid content of the ethanol leaf extract of P. inquinans  (369.65mg of 
quercetin equivalent per gram of dried extract), the acetone extract (202.3mg quercetin 
equivalent per gram of dried extract) and aqueous extract (127.2mg quercetin equivalent per 
gram of dried extract) were much higher than that reported for the different solvents of leaf 
extract of   P. graveolens; aqueous extract 21.75mg of quercetin per gram(Hsouna and 
Hamdi, 2012). The ethanol extract had significantly higher (P < 0.05) levels than the acetone 
and aqueous extract. Flavonoids as was reported earlier, have antioxidative, anti-
inflammatory and antineoplastic effects (Aggarwal and Harikumar, 2008). Pelargonium spp. 
leaves are known to be rich in flavonoids, with flavonols being the major subclass 
(Saraswathi et al., 2011). This study also shows the rich flavonoid content of leaf extracts of 
P. inquinans. 
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   The flavonol content of the leaf extracts in this study (Fig 4) showed acetone leaf extract 
(35.67mg of quercetin equivalent per gram of dried extract) was slightly higher than the 
ethanol leaf extract (34.52mg of quercetin equivalent per gram of dried extract).The water 
extract was the lowest at 16.42mg of quercetin equivalent per gram of dried extract. The 
acetone and ethanol extract had significantly higher (P<0.05) levels than the aqueous extract. 
This result showed a similar trend to the study reported by Karatoprak et al. (2017) done on 
root extracts of P. endlicheranum. However, the ethanol extract obtained in this study was 
higher than that reported for P. endlicheranum. Flavonols have good antioxidant and anti-
inflammatory activities and are readily distributed in the leaves of Pelargonium spp. Dietary 
flavonol intake has been shown to be associated with low risk of breast cancer (Adebamowo 
et al., 2005).  
   The proanthocyanidin levels in this study were low compared to its flavonoid content. The 
highest content was in the acetone leaf extract (10.4mg of catechin equivalent per gram of 
dried extract). The ethanol and aqueous extracts yielded 8.8 and 5.33mg of catechin 
equivalent per gram of dried extract respectively. Proanthocyanidins are a group of 
phytochemicals that are readily found in many medicinal plants and are known for their 
powerful antioxidant activities (Shi et al., 2003). However, they are also known to have anti-
adhesive activities (Janecki et al., 2011). Proanthocyanidin oligomers have been 
characterized in root extracts of P. sidoides (Schotz and Noldner, 2006), but they have only 
moderate pharmacological effects. 
   Pelargonium spp. have been observed to be a rich source of tannins. In this study high 
levels of tannins were observed in the acetone leaf extract of P. inquinans (123.8mg/g GAE 
per gram of dried extract) compared to the ethanol (73.3mg/g GAE per gram of dried extract) 
and aqueous leaf extracts (41.3mg/g GAE per gram of dried extract). The acetone extract 
showed significantly higher (P< 0.05) levels than the ethanol and the aqueous extracts, and 
the ethanol showed significantly higher (P< 0.05) levels than the aqueous extract. The results 
of this study were similar to what was reported by Petlevski et al. (2013) for the total tannin 
content using water and ethanolic leaf extracts of P. radula, though the result of their aqueous 
extract was significantly lower than the one obtained in our study. Although tannins have 
been reported to be anti-nutritive, they have been discovered to possess biological and 
pharmacological actions such as antimicrobial, antineoplastic, anti-plasmin inhibitory activity 
as well as superoxide anion scavenging activity (Okuda and Ito, 2011). Geraniin, a 
dehydroellagitannin found in Pelargonium spp., especially Geranium thunbergii, has been 
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shown to play an inhibitory role in human melanoma cells by mediating apoptosis through 
the cleavage of focal adhesion kinase and up-regulation of Fas ligand expression (Lee et al., 
2008). 
   The Pelargonium spp. have been reported to have some alkaloids (Saraswathi et al., 2011), 
though made up of primary polyphenols. The indole alkaloids elaeocarpidine and its 20-H 
isomer epielaeocarpidine were characterized in the leaves of the Pelargonium appleblossom 
(Lis- Balchin, 1996). Also recently, Igwenyi and Elekwa (2014) were able to quantify the 
total alkaloid content of the fresh leaves of  Geranium robertianum from Nigeria. In this 
study, the alkaloid content from the pulverized sample of P. inquinans was 0.52% (Table 9). 
The results were lower than what was obtained by Igwenyi and Elekwa (2014), who appears 
to be the first to quantify the alkaloid content of Pelargonium inquinans. The 
pharmacological importance of alkaloids cannot be understated especially as anticancer 
agents in the management of many malignancies. 
   In this study, saponin was also found in the pulverized leaf sample (Table 9). The presence 
of saponin in Pelargonium spp. is well documented. Saponin was present in all the solvent 
extracts of  P. graveolens leaves, in a qualitative screening done by Pradeepa et al. (2016) 
Saponin was also observed in P.luridum (Saheed and Ashafa, 2016), although the saponin 
content quantified in Geranium robertianum was low (Igwenyi and Elekwa, 2014). In this 
study, the saponin content was moderate. Saponins are known to have medicinal values 
which include anti-inflammatory, cholesterol-lowering activity as well as antineoplastic 
activity. The antineoplastic activity is reported to be achieved via anti-angiogenesis and anti-
metastasis (Zeng et al., 2015; Xu et al., 2016). The saponin content could be partly 
responsible for the cytotoxicity of  Pelargonium. inquinans. To the best of our knowledge, 
this is the first study to report the saponin content in Pelargonium. inquinans leaves.  
   Phytate is also known to be anti-nutritive but has been discovered to have some health 
benefits. Some of their pharmacological activity includes lowering of blood sugar and lipids, 
antioxidants, and prevention of nephrolithiasis (Schlemmer et al., 2009).The phytate content 
of  P. inquinans was low in comparison to the other phytochemicals in this study (Table 9).  
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Table 9: Anti-nutrient composition of Pelargonium inquinans leaves 
Anti-nutrient Content (%) 
Saponin  36.2 ± 4.38 
Alkaloid  0.52 ± 0.10 
Phytate  0.65 ± 0.07 
  
    
 
 
2.3.3 Vitamins content of Opuntia stricta  
   Vitamins A, E, and C were present in the dried cladodes of Opuntia stricta (Table 10). The 
highest vitamin content was vitamin A at 711.2 mg/100g of dried extract. The vitamin E 
content was 231.4 mg /100g of dried extract. The vitamin C content was the least of all the 
measured vitamins at 2.9mg /100g of dried extract. The vitamin A result was higher than 
what was reported by Fernandez- Lopez et al. (2010), though the latter reported the contents 
of Opuntia stricta in fresh fruits (4.71±0.10 μg β-carotene equivalents/100 g). The vitamin E 
content result was lower than what El-Mostafa et al. (2014) reported for Opuntia ficus indica 
(527.4; 106; 2182 mg/100g). While this study reported the cladodes, their study reported the 
pulp, seeds, and skin. The vitamin C content was lower than what Kuti (2004) reported for 
Opuntia stricta (815 μg/g). The latter was also reported in fresh fruits rather than dried 
cladodes. 
   Vitamins are a well-known nutrient that contributes to health and well-being. Although 
needed in small amounts they play a vital role in normal body physiology, and their 
deficiencies have been linked to some diseases (Traber and Stevens, 2011). Vitamin C and E  
are a well-known antioxidant that plays major roles in cells that display oxidative stress 
including cancer cells (Montecinos et al., 2007; Rizvi et al., 2014).  Vitamin A derivatives 
such as all-trans- retinoic acid are used in the management of acute promyelocytic leukaemia 
(Sanz et al., 2010).  Some of these vitamins and their derivatives have been mooted as 
chemopreventive agents (Freemantle et al., 2003). The discovery of more dietary sources of 
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vitamins and their derivatives like Opuntia spp. can be a way to prevent cancers. More 
clinical research is needed to prove this. 
Table 10: Vitamin contents of Opuntia stricta cladodes (dried extract) 
Vitamin Mean ± SD (mg/100g) 
Vitamin A 711.2 ± 4.2 
Vitamin E 231.4 ± 18.6 
Vitamin C 2.9 ± 0.08 
 
2.3.4 Vitamins analysis of Pelargonium inquinans 
   This study observed vitamins A, E, and C in the dried leaves of Pelargonium inquinans 
(Table 11). The highest vitamin content was vitamin A at 1.9g/100g of dried extract. The 
vitamin E content was 280.9mg /100g of dried extract while the vitamin C content was 2.0mg 
/100g. A search of the literature revealed little about vitamin contents in Pelargonium spp. 
The study by Igwenyi and Elekwa (2014) on fresh leaves of Geranium robertianum reported 
lower levels of vitamin A (1.44mg/100g) and vitamin E (0.016mg/100g) than that obtained in 
this study, while the vitamin C content was higher than that observed in this study 
(14.75mg/100g).  Vitamins are a well-known nutrient that contributes to health and well-
being. Although they are needed in small amounts they play a vital role in normal body 
physiology, and their deficiencies have been linked to some diseases (Traber and Stevens, 
2011). Vitamin C and E  are well-known antioxidants that play major roles in cells that 
display oxidative stress including cancer cells (Rizvi et al., 2014; Montecinos et al., 2007).  
Vitamin A derivatives such as all-trans- retinoic acid are used in the management of acute 
promyelocytic leukaemia (Sanz et al., 2010).  Some of these vitamins and their derivatives 
have been mooted as chemopreventive agents (Freemantle et al., 2003). The discovery of 
more sources of these vitamins and their derivatives like Pelargonium spp. can be a way to 
prevent cancers. More clinical research is needed to prove it.   
Table 11: Vitamin contents of Pelargonium inquinans leaves (dried weight) 
Vitamin Mean ± SD (mg/100g) 
Vitamin A 1900 ± 16.4 
Vitamin E 280.9 ± 26.2 
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Vitamin C 2.0 ± 0.02 
 
2.4 Antioxidant activity 
2.4.1 Nitric oxide scavenging activity 
   Nitric oxide is a well known free radical with pleiotropic effects across some physiological 
processes in the body (Besco et al., 2012). It is known to play a role in vasodilatation, smooth 
muscle relaxation, inhibition of platelet aggregation, immunity (Jagetia et al., 2002). It is 
constitutively produced by the body in nanomolar concentration to maintain normal cellular 
function. However, nitrous oxide produced in greater concentration can exacerbate 
inflammatory processes causing tissue damage. In this study, all the extracts of Opuntia 
stricta scavenged nitrous oxide in a dose-dependent decreasing manner, i.e., the 
concentration was inversely proportional to the scavenging activity (Fig 5). All the extracts 
and the standards exhibited their highest scavenging activity at 0.1mg/ml in a concentration-
dependent decreasing manner,  and it was in the order ethanol> vitamin C > gallic acid > 
acetone > aqueous (Figure 5). 
 These results were similar to that Saravanakumar et al. (2015) obtained with Opuntia ficus 
indica, though they worked with fruits. This study shows that all the extracts of Opuntia 
stricta cladodes evaluated can scavenge nitrous oxide and could be used in the management 
of some chronic ailments that cause oxidative stress.   
 
Figure 5: Nitric oxide radical scavenging activity of the extracts of Opuntia stricta cladodes.  
The values represent mean ± S.D (n=3). P < 0.05. 
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   In this study, the acetone, aqueous and ethanol extracts of Pelargonium inquinans leaves 
exhibited a high capacity to scavenge nitrous oxide radicals in a dose-dependent decreasing 
manner, i.e. the concentration was the inverse of scavenging activity. The aqueous extracts of 
the plant showed the highest activity at 0.1mg/ml (61.4% ± 0.03), higher than the ethanol 
extract at 60% ± 0.01 and aqueous extract at 58.7% ± 0.01 (Figure 6). The acetone extract 
also had greater activity than gallic acid (44.5% ± 0.05) and Vitamin C (52% ± 0.03). The 
values were statistically significant (p< 0.05).  
  The Pelargonium spp. are known to have good antioxidant activity especially their essential 
oils (Saraswathi et al., 2011). A search of the literature did not show records of antioxidant 
activity of Pelargonium inquinans, neither did it show records of nitrous oxide radical 
scavenging activity done in other Pelargonium spp. This study appears to be the first to do 
the antioxidant activity of Pelargonium inquinans crude extracts through nitrous oxide 
scavenging. 
  
Figure 6: Nitric oxide radical scavenging activity of the extracts of Pelargonium inquinans 
leaves.  
The values represent mean ± S.D (n=3).P <0.05. 
 
2.4.2 DPPH radical scavenging activity 
   Alpha, alpha-diphenyl- β-picrylhydrazyl (DPPH) is a stable free radical that reacts slowly 
with most compounds. The method was developed by Blois in 1958 and is based on the 
ability of the odd nitrogen electron in its molecules to accept a hydrogen atom from a donor 
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antioxidant thereby becoming reduced in the process, i.e., DPPH-H (Kedare and Singh, 
2011). The result of this study (Figure 7) showed that the acetone, ethanol and aqueous 
extracts had almost equal scavenging activity with DPPH at all concentrations. The DPPH 
scavenging activity of the acetone, aqueous and ethanol extracts at their optimal 
concentration (0.2mg/ml) were 73.66% ± 0.01, 73.04%  ± 0.003 and 73.79% ± 0.01 
respectively. None of the extracts had activity as potent as either vitamin C or gallic acid at 
84.9% ± 0.01 and 84.65% ± 0.03. These results are similar to that reported by Kunyanga et 
al. (2014) on the fruits of Opuntia stricta and Saravanakumar et al. (2015) with Opuntia ficus 
indica fruits. The DPPH radical scavenging activity of the three extracts did not show any 
significant differences (P> 0.05). The results confirmed the anti-oxidant properties Opuntia 
stricta extracts. 
 
Figure 7: DPPH radical scavenging activity of the extracts of Opuntia stricta cladodes.  
The values represent mean ± S.D (n=3). P > 0.05. 
 
   The three solvent extracts of P. inquinans evaluated scavenged DPPH efficiently (Fig. 8). 
Their scavenging activity at optimal concentration (0.2mg/ml) was similar and not 
statistically different in a dose-dependent decreasing manner, i.e., the concentration was the 
inverse of scavenging activity. The ethanol extract exhibited the highest scavenging activity 
at 82.7%  ± 0.01 followed by acetone and aqueous extracts at 82.29% ± 0.01 and 82.25% ± 
0.003% respectively.  All the extracts had lower activity than the standards- vitamin C 
(84.9%  ± 0.01 ) and gallic acid (84.65%  ± 0.04) (Figure 8).  
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   The DPPH scavenging activity of the acetone extract of P. inquinans recorded in this study 
was higher than that reported for the acetone extract of Geranium macrorrhizum (Miliauskas 
et al.,2004), though the latter's methanolic extract was higher than Pelargonium inquinans'. 
Similarly, Sabry (2013), reported that the methanolic extract of Pelargonium graveolens 
showed slightly higher scavenging activity than any of the three extracts in this study. 
Pelargonium inquinans has also been shown to exert strong DPPH scavenging with its ethyl 
acetate fraction showing excellent antioxidative potential (Piao et al., 2008). The compound 
1,2,3,4,6-penta-O-galloyl-beta-d-glucose (PGG) is taken as the active antioxidative 
component. The Pelargonium spp are known to possess antioxidative activity. This study 
further confirmed it.  
 
Figure 8: DPPH radical scavenging activity of the extracts of Pelargonium inquinans leaves. 
 The values represent mean ± S.D (n=3). P > 0.05. 
 
2.4.3 Phosphomolybdenum antioxidant activity 
   The phosphomolybdenum antioxidant assay is a quantitative method based on the reduction 
of phosphate-molybdenum (VI) to phosphate-molybdenum (V). This antioxidant assay 
evaluates the total antioxidant capacity (water-soluble and fat-soluble) of a crude extract. In 
this study, the aqueous extract of Opuntia stricta exhibited the highest total antioxidant 
capacity at 67.87% ± 0.004. The acetone and the ethanol extracts had activities of 66.15%  ± 
0.006 and 65.97% ± 0.001 respectively. The total antioxidant capacity was dose-dependent 
with a decrease in activity observed as extract concentration increased. The scavenging 
activity of the three extracts was not significantly different and was higher than that for 
vitamin C and gallic acid (Figure 9). The water extract had a higher quantitative antioxidant 
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capacity than the other solvents. This increased antioxidant capacity can be explained by the 
fact that water is more polar than the other solvents (Tian et al., 2009). This fact was also 
observed by Dib et al. (2013) when investigating the total antioxidant capacity of cladodes of 
Opuntia ficus indica. This study confirms the antioxidant capacity of Opuntia stricta 
cladodes, and its ability to mop up free radicals. 
 
Figure 9: Phosphomolybdenum (total) antioxidant activity of the extracts of Opuntia stricta 
cladodes. The values represent mean ± S.D (n=3). P > 0.05. 
 
    The aqueous extract of Pelargonium inquinans exhibited a greater antioxidant capacity 
than the ethanol and acetone extracts. Their antioxidant capacity was in the order aqueous > 
ethanol > acetone although less than vitamin C and gallic acid. (Figure 10). This increased 
total antioxidant capacity still explains the solvent polarity of the fractions used. Pelargonium 
spp. are known to have the good antioxidant capacity. However a search of the literature did 
not reveal any phosphomolybdenum antioxidant capacity work done before, and neither did it 
reveal any too for Pelargonium inquinans.  
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Figure 10: Phosphomolybdenum (total) antioxidant activity of the extracts of Pelargonium 
inquinans leaves. The values represent mean ± S.D (n=3). P > 0.05. 
 
2.4.4 Hydrogen peroxide scavenging activity 
   Hydrogen peroxide is an important reactive oxygen species that is formed as a result of the 
enzymatic conversion of superoxide radical by superoxide dismutase. It is then either 
converted to water by catalase or to hydroxyl radical in the Fenton reaction. Hydrogen 
peroxide is cytotoxic to cells, and it is used by the body to fight bacterial and also to enhance 
the process of inflammation (Halliwell et al., 2000). The product of hydrogen peroxide 
catalysis, hydroxyl ion is regarded as the most reactive of all reactive oxygen species capable 
of causing lipid peroxidation, protein damage and membrane damage (Sharma et al., 2012). 
Due to its role in inflammation and cell damage, control of the cellular level of hydrogen 
peroxide is important. 
   In this study, the aqueous extract of Opuntia stricta cladodes had the highest scavenging 
activity of all the extracts used. The scavenging activity of the extracts were in the order 
aqueous 98.63%  ± 0.01> acetone 98.6% ± 0.01 > ethanol at 98.52% ± 0.01. The differences 
were however negligible and not statistically significant (P>0.05), and neither was the 
aqueous extract significantly higher than vitamin C and gallic acid (Figure 11). The results 
obtained in this study was different from what  Saravanakumar et al. (2015) reported for 
Opuntia ficus indica. The two methodologies were also different.  
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Figure 11: Hydrogen peroxide scavenging activity of the extracts of Opuntia stricta 
cladodes.  
The values represent mean ± S.D (n=3). P > 0.05. 
 
   For Pelargonium inquinans, aqueous extracts of the leaves used had the highest scavenging 
activity of all the extracts used. The scavenging activity of the extracts were aqueous 98.39%  
± 0.009; acetone 97.11% ± 0.008 and ethanol at 96.99% ± 0.04. The differences were 
however negligible. There were no significant differences in the activity (P>0.05). The 
aqueous extract was also slightly lower than vitamin C and gallic acid (Figure 12). A search 
of the literature did not reveal any information about hydrogen peroxide scavenging ability of 
Pelargonium inquinans. However, coumarins, compounds consisting of fused benzene and 
alpha pyrone rings are found abundantly in Pelargonium spp. (Saraswathi et al., 2011).  A 
study reported the hydrogen peroxide scavenging activity of some coumarin derivatives 
showed that some of them have high hydrogen peroxide scavenging activity (Al- Almiery et 
al., 2015), which may explain the high activity observed in all the extracts of Pelargonium 
inquinans.  
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Figure 12: Hydrogen peroxide scavenging activity of the extracts of Pelargonium inquinans 
leaves extracts. The values represent mean ± S.D (n=3). P > 0.05. 
 
2.5 CONCLUSION 
   The results obtained in this study have shown that Opuntia stricta and Pelargonium 
inquinans have bioactive compounds in the leaves of the plants used. The plants are also rich 
in vitamins.  
   Different Opuntia spp. have been used for many centuries as both food and medicine by 
traditional communities. It has long been used in the management of many chronic conditions 
like diabetes and metabolic syndrome, and also acute conditions like burns. This study has 
shown that Opuntia spp. has phytochemicals and vitamins that play a role in the active 
management of some diseases, and the traditional healers were justified. With its antioxidant 
properties, there is a need for a more scientific approach to understand better the biochemical 
activities and how to harness their potentials towards chronic diseases like leukaemia as 
chemopreventive antioxidant agents. 
   The Pelargonium spp. have been used by traditional healers in South Africa for a long time, 
and some of them have found use in pharmaceuticals in Western countries. This study has 
shown they are rich in polyphenols as well as vitamins which influenced many of their uses. 
There is a need for more scientific studies to isolate and characterise some of their 
compounds and perhaps perform some in vivo experiments as well as clinical studies to 
ascertain their efficacy also as chemopreventive antioxidant agents against leukaemia. 
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CHAPTER 3 
 
3.1 INTRODUCTION 
 
   Essential oils are liquid preparations (some are solid or resinous at room temperature) 
usually extracted from aromatic plants. They are volatile,  translucent and soluble in organic 
solvents. For centuries essential oils have been used for various purposes, including 
medicinal, food, cosmetics, and agriculture. (Perricone et al., 2015). They also play a vital 
role in the protection of plants against predators where they act as antiviral, antifungal, 
antibacterial and insecticides.  
   Essential oils can be extracted through various methods. These methods include microwave 
assisted distillation, hydrodistillation, steam distillation and organic solvent extraction. 
Climate, seasonal variations, and soil composition can have qualitative and quantitative 
effects on the chemical profile of essential oils products as well as the extraction method 
(Bakkali et al., 2008). Essential oils are known to exhibit a host of biological activities such 
as anti-inflammatory (Silva et al., 2003), anti-oxidative (Miguel, 2010) and anti-cancer  
properties (Yang et al., 2017). According to Omoruyi et al. (2014),  essential oils are used in 
South Africa as food preservatives against micro-organisms, which makes them relatively 
cheap and readily available. 
   The first published work on the antineoplastic activity of essential oils dates back to the 
1960s according to Bayala et al. (2014). Since then, the effect of essential oils on various 
types of cancer has been reported. For example geranium essential oils from Pelargonium 
spp. has shown antineoplastic activity against two human acute promyelocytic cell line, HL-
60, and NB4 (Saraswathi et al., 2011). 
   Opuntia stricta and Pelargonium inquinans albeit from different families are known to 
produce essential oils (Moosazadeh et al., 2014; Elbadri et al., 2008). Both plants are known 
to have antioxidant and anti-inflammatory properties (Osuna-Martinez et al, 2014; 
Boukhatem et al, 2013). A search of current literature indicates that the essential oils of 
Opuntia stricta cladodes and Pelargonium inquinans leaves have not been analyzed before in 
South Africa. This study will endeavour to identify bioactive compounds with therapeutic 
potentials especially those with anti-inflammatory and antineoplastic properties in the 
essential oils of Opuntia stricta cladodes and Pelargonium inquinans leaves.  
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3.2 Materials and Methods 
3.2.1 Plant material and isolation of oil 
   The leaves of Pelargonium inquinans and Opuntia stricta were collected as previously 
described in section 2.2.1. 400g of fresh cladodes of Opuntia stricta and fresh leaves of 
Pelargonium inquinans were used. The plant materials were hydrodistilled in a Clavenger's 
apparatus for 3hours as described by Moosazadeh et al. (2014). The oil was put in dark, 
tightly closed vials and kept in the fridge at 40C until analyses. 
 
3.2.2 GC-MS analysis 
   The GC-MS analysis was performed as described by Sagbo (2015). The analysis was 
performed using Agilent 6890 GC coupled to Agilent 5975 MSD with a Zebron-5MS column 
(ZB-5MS 30 m x 0.25 mm x 0.25 um). GC grade helium was used as a carrier gas at a flow 
rate of 2 mL/min; splitless one µL injections were used. The temperature of the injector was 
280oC; the source  280oC, the oven 70oC, the ramp was 15oC/min. to 120oC, then  10oC/min 
to 180oC, then 20oC/min. to 270oC and held for 3 minutes. 
 
3.2.3 Calculation of yield 
   The oil yield was calculated using the following equation: 
Percentage (%) yield = [(B- A) ÷ X] 100 where Mass of plant material distilled (g) = X; Mass 
of empty bottle (g) = A; Mass of bottle + oil extracted = B; Mass of oil (g) = (B-A). 
 
 
3.2.4 Identification of compounds 
   The compounds present in the essential oils were identified by matching their spectral mass 
against the National Institute of Standards and Technology (NIST) 11 database (http//: 
nist.gov). 
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3.3 RESULTS AND DISCUSSION 
 
   The yields of the essential oils were 0.2% and 0.23% for the fresh samples of Opuntia 
stricta and Pelargonium inquinans respectively. 46 compounds were identified in the 
essential oils of Opuntia stricta, while 109 compounds were identified in Pelargonium 
inquinans. The compounds with the largest yield (according to their % peak areas) in 
Pelargonium inquinans included caryophyllene (22.02%), sesquicineole (14.63%), humulene 
(11.92%), beta myrcene (9.15%), alpha-pinene (1.13%) and trans-.alpha.-Bergamotene 
(1.1%). For Opuntia stricta they were beta-copaene (7.54%), octasiloxane 1,1,3,3,5,5,9,9, 
11,11,13,13,15,15- hexadecamethyl- (4.75%) , Cyclotrisiloxane, hexamethyl- (3.83%), alpha-
pinene (3.12%), alpha.-Ionone (2.45%), and 5-Methyl-2-trimethylsilyloxy-acetophenone 
(2.33%) . The range of compounds in both plants consisted of monoterpenes, cyclic terpenes, 
sesquiterpenes, fatty acids, phenols, alcohols, and aromatic compounds. The tables below list 
the various compounds found in the essential oils of the plants studied. 
 
3.3.1Pharmaceutical properties 
Many of the compounds found in these plants have been found to have pharmacological 
activities. These activities include antioxidant, anti-inflammatory and also antineoplastic 
(Shabaan et al., 2012).  
 
3.3.2 Antioxidant properties 
Essential oils are known to have antioxidant properties (Grassmann et al., 2000). In this 
study, some compounds with antioxidant properties were noted. These include camphene 
(Tiwari and Kakkar, 2009), D-limonene (Yu et al., 2017), 3-carene (Aazza et al., 2011), 
terpinene (Rudback et al., 2012) and some others found in Pelargonium inquinans.  Alpha-
pinene (Singh et al., 2006), heptadecane (Kim et al., 2013), beta-ionone (Assokumar et al., 
2012)and some other compounds were found in Opuntia stricta in this study, and are also 
known to exhibit antioxidative properties. Beta copaene, a tricyclic sesquiterpene was the 
highest component found in Opuntia stricta with some small amount also found in 
Pelargonium inquinans.  Beta copaene is known to have antioxidant activity (de Santi et al., 
2017).  
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3.3.3 Anti-inflammatory properties 
Essential oils are known to have anti-inflammatory properties (Tung et al., 2008). In this 
study, some compounds with anti-inflammatory properties were noted. These include gamma 
terpinene (Ramalho et al., 2015), alpha phellandrene (Siquiera et al., 2016), Isoeugenol 
(Khan, 2014) and some other compounds found in Pelargonium inquinans.  
Beta copaene and beta cadinene both found in Opuntia stricta in this study, are also known to 
act as an anti-inflammatory (De Oliveira et al., 2012; Zhang et al., 2014). Eugenol and 
globulol, both aromatic compounds found in Pelargonium inquinans and Opuntia stricta in 
this study are known to have anti-inflammatory activities (Beg et al., 2011; Huang et al., 
2015).   
 
 
3.3.4 Antineoplastic properties 
Over the last decade, more studies have focused on essential oils as antineoplastic agents 
(Guatam et al., 2014). Some constituents of essential oils are known to have antineoplastic 
potentials. Some of the compounds in this study with antineoplastic potentials from different 
studies include monoterpenes, sesquiterpenes, and sterols. Caryophyllene, a member of the 
bicycle sesquiterpene, commonly found in Piper nigrum, Cannabis sativa and Rosmarinus 
officinalis (Fidyt et al., 2016) was the highest component in Pelargonium inquinans. 
Caryophyllene is known to have antineoplastic (Fidyt et al., 2016), anti-inflammatory (Sain et 
al., 2014), and antioxidant (Sitarek et al.,2017) properties. Alpha-terpineol, a volatile 
monoterpenoid alcohol, also observed in the essential oil of Pelargonium inquinans has been 
found to exhibit antineoplastic activity against some cancers (Hassan et al., 2010).  Beta-
Sitosterol, a phytosterol is known to have antineoplastic properties (Bin Sayeed and Ameen, 
2015). Alpha-pinene, beta-ionone and terpinolene found in Opuntia stricta in this study are 
also known to exhibit antineoplastic properties (Okumura et al., 2012; Chen et al., 2015; 
Faezizadeh et al., 2016). 
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       Figure 13: GC-MS chromatogram of essential oil of Pelargonium inquinans  
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Table 12: Chemical composition of  P. inquinans essential oil determined by GC-MS 
S/N 
RT 
(mins) Compounds 
Peak 
(%) 
Structure 
(ChemSpider) 
Molecular 
formula Function MW 
Hit 
quality 
1. 3.187 
10-Iododecyl trimethylsilyl 
ether 0.01  C13H29IOSi  356 25 
2. 3.269 3-Hexen-1-ol 0.10  C6H12O  100 76 
3. 3.34 Oxirane OR Ethylene Oxide 0.02  C2H4O  44 59 
4. 3.598 
Cyclohexasiloxane 
dodecamethyl 0.04  C12H36O6Si6  444 20 
5. 3.861 3-Carene 0.06  C10H16 
Anti-
inflammatory 136 78 
6. 3.943 alpha.-Pinene 1.13  C10H16 
Antineoplastic, 
anti-
inflammatory. 
antioxidant 136 97 
7. 3.943 gamma.-Terpinene 1.13  C10H16 
Antineoplastic, 
anti-
inflammatory, 
antioxidant 136 91 
8. 4.081 Camphene 0.76  C10H16 
Antineoplastic, 
antioxidant 136 97 
9. 4.211 Diacetylmorphine 0.02  C21H23NO5  369 25 
10. 4.331 beta.-Myrcene 9.15  C10H16 
Antineoplastic, 
anti-
inflammatory, 
antioxidant 136 91 
11. 4.331 beta.-Pinene 9.15  C10H16 
Antineoplastic, 
anti-
inflammatory, 
antioxidant 136 58 
12. 4.391 Cosmene 0.48  C10H14  134 95 
13. 4.391 1,3,8-p-Menthatriene 0.48  C10H14  134 87 
14. 4.495 alpha.-Phellandrene 0.05  C10H16 
Antineoplastic, 
anti-
inflammatory 136 72 
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15. 4.549 1,4-Cyclohexadiene,1-ethyl- 0.21  C8H12  108 53 
16. 4.596 -2-Carene 0.05  C10H16  136 96 
17. 4.694 D-Limonene 0.96  C10H16 
Antineoplastic, 
anti-
inflammatory, 
antioxidant 136 98 
18. 4.85 Butanoic acid, pentyl ester 0.06  C9H18O2  158 59 
19. 4.938 1-Octanol 0.47  C8H18O  130 91 
20. 5.052 Nortricyclene 0.10  C7H10  94 45 
21. 5.091 Toluene 0.05  C7H8  92 22 
22. 5.199 Isopulegol acetate 0.63  C12H20O2 antioxidant 196 38 
23. 5.239 Nonanal 0.39  C9H18O  142 38 
24. 5.336 4-Methyl-1,5-Heptadiene 0.36  C8H14  110 53 
25. 5.575 Ipsdienol 0.12  C10H16O antioxidant 152 62 
26. 5.623 Butyl 2-methylvalerate 0.04  C10H20O2  172 53 
27. 5.717 
1-Propene, 3-methoxy-2-
methyl- 0.05  C5H10O  86 49 
28. 5.798 1,3-Cycloheptadiene 0.06  C7H10  94 50 
29. 5.902 Terpinen-4-ol 0.3  C10H18O 
Antineoplastic, 
anti-
inflammatory, 
antioxidant 154 96 
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30. 5.989 alpha.-Terpineol 0.62  C10H18O 
Antineoplastic, 
anti-
inflammatory, 
antioxidant 154 96 
31. 5.989 (+)-4-Carene 0.62  C10H16  136 46 
32. 6.196 Ionene 0.23  C13H18 
Antineoplastic, 
anti-
lnflammatory 174 95 
33. 6.235 beta-cyclocitral 0.03  C10H16O  152 72 
34. 6.451 dimethyl fumarate 0.03  C6H804 
Anti-
inflammatory 144 35 
35. 6.699 decyl disulfide 0.23  C20H42S2 
Antineoplastic 
analogue 346 40 
36. 6.885 2-Pentene, 3-methyl-, (E)- 0.04  C6H12  84 49 
37. 6.945 1,1,5,6 tetramethylindane 0.04  C13H18  174 93 
38. 7.175 Isoeugenol 0.56  C10H1202 
Antineoplastic, 
anti-
inflammatory, 
antioxidant 164 97 
39. 7.175 Eugenol 0.56  C10H1202 
Antineoplastic, 
anti-
inflammatory, 
antioxidant 164 98 
40. 7.226 Dehydro-ar-ionene 0.23  C13H16  172 97 
41. 7.335 Bornyl acetate 0.23  C12H1202 
Antineoplastic,a
nti-
inflammatory 196 95 
42. 7.398 alpha.-Farnesene 0.43  C15H24  204 43 
43. 7.398 
-3-Carene, 2-
(acetylmethyl)- 0.43  C13H20O  192 49 
44. 7.457 beta.-copaene 0.32  C15H24 antioxidant 204 68 
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45. 7.457 alpha elemene 0.32  C15H24  204 68 
46. 7.457 beta gurjunene 0.32  C15H24  204 68 
47. 7.607 trans-.alpha.-Bergamotene 1.10  C15H24  204 91 
48. 7.655 alpha santolol 0.10  C15H24O 
Antineoplastic, 
anti-
inflammatory 220 80 
49. 7.728 Caryophyllene 22.02  C15H24 
Antineoplastic, 
antioxidant, 
anti-
inflammatory 204 99 
50. 7.789 cis-.beta.-Farnesene 2.11  C15H24  204 96 
51. 7.836 Alloaromadendrene 0.14  C15H24 antioxidant 204 91 
52. 7.836 alpha Himachelene 0.14  C15H24  204 87 
53. 7.943 Humulene 11.92  C15H24 
Antineoplastic, 
anti-
inflammatory 204 97 
54. 7.943 Ocimene 11.92  C10H16 
Antineoplastic, 
anti-oxidant 136 97 
55. 7.998 beta.-curcumene 1.25  C15H24 
Anti-
inflammatory 204 87 
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56. 7.998 Di-epi-.alpha.-cedrene- 1.25  C15H24 antineoplastic 204 90 
57. 8.062 gamma.-Muurolene 0.28  C15H24 
Anti-
inflammatory 204 86 
58. 8.183 beta.-Bisabolene 5.52  C15H24 
Antineoplastic, 
anti-
inflammatory 204 96 
59. 8.183 cis-.alpha.-Bisabolene 5.52  C15H24  204 50 
60. 8.249 sesquicineole 14.63  C15H26O  222 95 
61. 8.373 Levomenol 0.42  C15H26O 
Anti-
inflammatory 222 64 
62. 8.373 alpha-Fenchene 0.42  C10H16  136 70 
63. 8.471 Nerolidol 2 0.54  C15H26O 
Antineoplastic, 
anti-
inflammatory 222 91 
64. 8.551 Squalene 0.58  C30H50 antineoplastic 410 72 
65. 8.551 Crotocin 0.58  C19H24O5  332 74 
66. 8.632 Hexadecane 0.31  C16H34  226 98 
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67. 8.632 Octadecane 0.31  C18H38 
Antineoplastic 
analogue 254 90 
68. 8.632 Nonadecane 0.31  C19H40  268 87 
69. 8.688 Caryophyllenyl alcohol 0.38  C15H26O  222 72 
70. 8.730 beta.-Sitosterol 0.07  C29H50O 
Antineoplastic, 
anti-
inflammatory, 
antioxidant 414 38 
71. 8.730 Geranylgeraniol 0.07  C20H34O 
Antineoplastic, 
anti-
inflammatory, 
antioxidant 290 43 
72. 8.765 alpha silenene 0.36  C15H24  204 89 
73. 8.847 Beta silenene 0.46  C15H24  204 89 
74. 8.911 cedrol 1.48  C15H26O 
Antineoplastic, 
anti-
inflammatory, 
antioxidant 222 95 
75. 8.911 epicedrol 1.48  C15H26O 
Antineoplastic, 
anti-
inflammatory 222 53 
76. 8.976 gamma cadinene 1.28  C15H24 
Anti-
inflammatory, 
antioxidant 204 83 
77. 8.976 beta cedrene 1.28  C15H24  204 78 
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78. 9.064 1-Cyclopentylcyclopentene 0.78  C10H16  136 78 
79. 9.064 1,6-Cyclodecadiene 0.78  C10H16  136 70 
80. 9.104 Ergost-5-en-3-ol, (3.beta.)- 0.45  C28H48O  400 70 
81. 9.167 beta.-bisabolol 0.77  C15H26O 
Antineoplastic, 
anti-
inflammatory 222 86 
82. 9.167 Santolina triene 0.77  C10H16  136 45 
83. 9.207 Eicosane 0.11  C20H42  282 95 
84. 9.248 Alpha longipinene 0.81  C15H24  204 51 
85. 9.392 2'-deoxy-adenosine 0.10  C10H13N5O3 Antineoplastic 251 38 
86. 9.448 Ylangenol 0.13  C15H24O 
Anti-
inflammatory, 
antioxidant 220 42 
87. 9.608 Eicosane, 9-octyl- 0.05  C28H58  394 47 
88. 9.655 1-Octadecene 0.06  C18H36  252 91 
89. 9.725 Benzyl Benzoate 0.07  C14H12O2  212 92 
90. 9.725 Benzoin 0.07  C14H12O2  212 45 
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91. 9.887 Isopropyl myristate 0.19  C17H34O2 
Anti-
inflammatory, 
antioxidant 270 99 
92. 9.887 Pentadecanoic acid 0.19  C15H30O2  242 15 
93. 10.02 2-Pentadecanone, 0.09  C18H36O  268 91 
94. 10.091 P-cymene 6,10,14-trimethyl 0.03  C10H14  134 60 
95. 10.411 Methyl palmitate 0.07  C17H34O2 
Anti-
inflammatory 270 97 
96. 10.546 -3-Methyl-1-penten-3-ol 0.05  C6H12O  100 64 
97. 10.546 Isophytol 0.05  C20H40O  296 58 
98. 10.546 2-Propenamide 0.05  C3H5NO  71 52 
99. 10.668 Dibutyl Phthalate 0.25  C16H22O4  278 70 
100. 10.668 Monopentyl Phthalate 0.25  C13H16O4  236 38 
101. 10.775 Docosane 0.11  C22H46  310 91 
102. 10.896 Perillyl Acetate 0.12  C12H18O2 
Antineoplastic, 
anti-
inflammatory 194 35 
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103. 11.071 
N-Methyl-1-
adamantaneacetamide 0.0  C13H21NO  207 60 
104. 11.198 1-Nonadecene 0.10  C19H38  266 96 
105. 11.260 Methyl linoleate 0.14  C19H34O2 
Anti-
inflammatory 294 97 
106. 11.297 Linolenelaidic acid 0.14  C18H30O2  278 58 
107. 11.933 
5-Methyl-2-
trimethylsilyloxy-
acetophenone 0.01  C12H18  222 25 
108. 12.324 
2,4-
Dimethylbenzo[h]quinoline 0.07  C15H13N  207 43 
109. 12.451 Hexamethylcyclotrisiloxane 0.09  C6H18O3Si3  222 43 
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Figure 14: GC-MS chromatogram of essential oil of Opuntia stricta  
Table 13: Chemical composition of  O. stricta essential oil determined by GC-MS 
 
S/N RT 
(mins) 
Compounds Peak 
(%) 
Structure 
(ChemSpider) 
Molecular 
formula 
Function  MW 
Hit 
quality 
1 
3.534 
Dodecamethylcyclohexasiloxane 
0.3 
 
C12H36O6Si6  444 46 
2 
3.613 
Heptanal 
1.23 
 
C7H14O  114 97 
3 
3.613 
Hexanal, 3-methyl- 
1.23 
 
C7H14O  114 37 
4 
3.613 
Formamide, N,N-dimethyl- 
3.12 
 
C3H7NO  73 43 
5 
3.943 
alpha.-Pinene 
1.46 
 
C10H16 
Antineoplastic,  
anti-inflammatory. 
antioxidant 
136 95 
6 
4.242 
beta.-Phellandrene 
0.92 
 
C10H16 
Antineoplastic, 
anti-inflammatory. 
antioxidant 
136 91 
7 
4.695 
alpha ocimene 
0.92 
 
C10H16 Anti-inflammatory 136 55 
4.005.006.007.008.009.0010.0011.0012.0013.0014.0015.0016.0017.00
100000
150000
200000
250000
300000
350000
400000
450000
500000
550000
600000
650000
700000
750000
800000
850000
900000
950000
1000000
1050000
1100000
1150000
1200000
1250000
1300000
1350000
1400000
1450000
1500000
1550000
Time-->
Abundance
TIC: Opuntia_Fresh.D\ data.ms
 3.534
 3.610
 3.943
 4.248
 4.308
 4.695 5.034
 5.162
 5.237
 5.489
 6.024
 6.449
 6.704
 6.852
 6.956
 7.078
 7.168
 7.378
 7.459
 7.709
 7.786 7.934
 8. 22
 8.098
 8.193
 8.311
 8.630
 8.993
 .059
 9.133
 9.207
 9.755
 9.887
10.018
10.195
10.277
10.672
10.774
10.891
1.077
11.202
11.24911.356
11.703
11.904
2. 40
12.137
12.244
12.352
12.453
12.556
12.600
12.635.717
12.766
12.878
12.958
13.001
13.219
13.281
13.345
13.393.446
13.547
. 9
13.739
13.787
.831
13.938
14.004
14.157
14.317
14.364
14.451. 94
14.609
14.695
.7668
14.959
15.679
111 
 
8 
4.695 
sylvestrene 
0.95 
 
C10H16  136 60 
9 
5.034 
Linalool oxide 
1.05 
 
C10H18O2 
Antineoplastic,  
anti-inflammatory. 
antioxidant 
170 59 
10 
5.237 
Nonanal 
1.05 
 
C9H18O  142 68 
11 
5.237 
Cycloheptane 
0.36 
 
C7H14  98 47 
12 
6.024 
N-Nitroso-di-n-octylamine 
2.45 
 
C16H34N2O  270 27 
13 
6.704 
Terpinolene 
2.45 
 
C10H16 
Antineoplastic,  
anti-inflammatory. 
antioxidant 
136 70 
14 
6.704 
beta- Ionone 
2.45 
 
C13H20O 
Antineoplastic,  
anti-inflammatory. 
antioxidant 
192 70 
15 
6.704 
alpha- Ionone 
0.83 
 
C13H20O 
Antineoplastic, 
 anti-inflammatory, 
antioxidant 
192 70 
16 
6.852 
Theaspirane 
0.52 
 
C13H22O 
Anti-inflammatory, 
antioxidant 
194 58 
17 
6.956 
Trans-decalin 
0.52 
 
C10H18  138 50 
18 
6.956 
Gephyrotoxin 181b 
0.88 
 
C19H29NO  287 50 
19 
7.378 
Octadecane, 1-iodo- 
7.54 
 
C18H37I  380 25 
20 
8.098 
beta.-copaene 
7.54 
 
C15H24 
Antineoplastic, 
antioxidant 
204 93 
21 
8.098 
Gemacrene D 
1.5 
 
C15H24 
Antineoplastic, 
anti-inflammatory 
204 96 
22 
8.311 
Beta Cadinene 
1.5 
 
C15H24 
Antineoplastic, 
anti-inflammatory 
204 95 
23 
8.311 
Delta Amorphene 
1.5 
 
C15H24 
Antineoplastic, 
anti-inflammatory 
204 91 
24 
8.63 
Hexadecane 
1.5 
 
C16H34  226 99 
25 
8.63 
Tetradecane 
1.5 
 
C14H30  198 96 
26 
8.63 
Octadecane 
0.86 
 
C18H38 
Antineoplastic 
analogue 
254 94 
27 
8.993 
Ledol 
0.86 
 
C15H26O 
Anti-inflammatory, 
antioxidant 
222 42 
28 
8.993 
Guaia-3,9-diene 
0.86 
 
C15H24  204 38 
29 
8.993 
(-)-Globulol 
0.68 
 
C15H26O 
Anti-inflammatory, 
antioxidant 
222 30 
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30 
9.133 
alpha-Cadinol 
0.68 
 
C15H26O antioxidant 222 94 
31 
9.133 
Alloisolongifolene 
0.38 
 
C15H24  204 46 
32 
9.207 
Heptadecane 
1.74 
 
C17H36 
Anti-inflammatory, 
antioxidant 
240 95 
33 
9.755 
Heneicosane 
1.96 
 
C21H44 
Anti-inflammatory, 
antioxidant 
296 94 
34 
9.887 
Isopropyl myristate 
1.96 
 
C17H34O2 
Anti-inflammatory, 
antioxidant 
240 99 
35 
9.887 
Palmitic acid 
1.47 
 
C16H32O2  256 25 
36 
10.277 
Nonadecane 
1.47 
 
C19H40 
Anti-inflammatory, 
antioxidant 
268 98 
37 
10.277 
Eicosane 
0.72 
 
C20H42  282 96 
38 
10.678 
Dibutyl phthalate 
0.63 
 
C16H22O4  278 92 
39 
10.891 
Isopropyl palmitate 
1.16 
 
C19H38O2 
Anti-inflammatory, 
antioxidant 
298 46 
40 
11.356 
Eicosane, 9-octyl- 
0.93 
 
C28H58  394 45 
41 
12.137 
Hexamethylcyclotrisiloxane 
0.72 
 
C6H18O3Si3  222 43 
42 
12.717 
2-Ethylacridine 
9.14 
 
C15H13N  207 43 
43 
13.219 
Diisooctyl phthalate 
9.14 
 
C24H38O4  390 90 
44 
13.219 
Bis(2-ethylhexyl) phthalate 
2.33 
 
C24H38O4 Pro-inflammatory 390 60 
45 
13.547 
5-methyl-2-trimethylsilyloxy-
acetophenone 
7.54 
 
C12H18  222 38 
46 
8.098 
beta Cubebene 
 
 
C15H24  204 94 
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3.4 Conclusion 
The GC-MS analysis of the volatile compounds in Pelargonium inquinans and Opuntia 
stricta indicate that the essential oils from both plants contain volatile compounds with 
pharmaceutical properties that can be effective in the treatment of leukaemia.  Further studies 
are required to isolate/synthesize the specific compounds and confirm their potential in the 
treatment of leukaemia. 
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CHAPTER 4 
 
4.1 Introduction 
   Inflammation is a complex interplay of the body’s responses to noxious stimuli which can 
be local or systemic to achieve tissue balance and homeostasis (Monteiro and Azevedo, 
2010). Inflammation can be acute or chronic. Acute inflammation is an immediate response 
to the endpoint of either extinguishing the stimulus or healing of tissue. Chronic 
inflammation, on the other hand, is a prolonged and maladaptive response that involves 
continuous inflammatory response, tissue destruction and an attempt at damage reversal 
(Weiss, 2008). Thus, most often chronic inflammation is a pathological condition. 
   The process of inflammation is mediated by different chemokines and cytokines (Turner et 
al, 2014). Their activity is in response to a stimulus which most often is a pathogenic insult. 
This pathogenic insult tends to activate macrophages. Lipopolysaccharide (LPS), a 
constituent of the outer membrane of the gram-negative bacteria is known to bind to the 
CD14 receptor on macrophages via the LPS- binding protein (LBP), which leads to the 
engagement of Toll-like receptor 4 (TLR4) which trigger the release of proinflammatory 
cytokines(Zhu et al, 2014). The release of the cytokines is achieved via the engagement of 
myeloid differentiation protein-88 (MyD88), Mal, toll-interleukin-1 receptor-related adaptor 
protein inducing interferon (TRIF) and TRIF-related adaptor molecule (TRAM) to the 
intracellular domain of TLR4. The nuclear factor-kB (NF-kB) and interferon-regulatory 
factor 3 (IRF3) pathways become activated by MyD88/Mal and TRIF/TRAM respectively. 
The mitogen-associated protein kinase (MAPK) family (ERK1/2, JNK, p38) also get 
involved. Pro-inflammatory cytokines are subsequently released by macrophages and other 
white cells. These cytokines include interleukin [IL]-1, IL-6, IL-12, TNF-alpha, macrophage 
migration inhibitory factor; anti-inflammatory cytokines (e.g. tumor growth factor (TGF) 
beta, IL-10), interferons, colony-stimulating factors, chemokines (IL-8, monocyte 
chemoattractant proteins [MCP], cyclooxygenase-2 (COX-2) and inducible nitric oxide 
synthase (iNOS) . The iNOS released generates nitrous oxide (NO) which along with some 
other mediators cause vasodilatation and often septic shock (Guzik et al., 2003).  NO has also 
been reported to mediate apoptosis and inhibition of tumour formation (Amirghofran et al., 
2011). 
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   Another mediator COX-2, which is generated during inflammation converts arachidonic 
acids into endoperoxides which produce series-2-prostaglandins and thromboxanes that 
mediate important biological processes (Ricciotti and FitzGerald, 2011). COX-2 is known to 
mediate cell proliferation and metastasis (Sobolewski et al., 2010) as well as mediate immune 
tolerance through the Indoleamine 2, 3-dioxygenase 1 (IDO1) pathway (Iachininoto et al., 
2013). Thus COX-2 inhibitors are seen as potential candidates in the management of cancers. 
Some medicinal plants have been used in the management of inflammatory conditions. They 
achieve this often by scavenging reactive oxygen/nitrogen species that are produced during 
the process of inflammation. Phytochemicals such as polyphenol compounds have been 
found useful as anti-inflammatory agents (Hussain et al., 2016). For example, curcumin and 
resveratrol are known to inhibit NF-kB (Gonzalez et al., 2011). Gamma terpinene, a 
monoterpene found in the essential oils of many plants including Pelargonium inquinans is 
known to modulate acute inflammation (Ramalho et al., 2015). Since inflammation is pivotal 
in many chronic diseases including cancers, targeting of inflammatory mediators especially 
through phytochemicals is a probable therapeutic option. 
4.2 Materials and methods 
4.2.1 Cell culture 
   The RAW 264.7 cells were obtained from the cell culture lab at the Department of 
Biochemistry, Nelson Mandela University. The RAW 264.7 cells were first suspended in 
DMEM/low Glucose solution supplemented with 10% heat-inactivated FBS and antibiotics 
(100 U/mL penicillin and 100 U/mL streptomycin) at 37 °C. The cells were stained with 
trypan blue and the number of viable cells counted using an inverted light microscope (Zeiss) 
and a Neubauer counting chamber (Hausser Scientific, USA Sigma Cat Z359629).The RAW 
264.7 cells were then put into the incubator at 37oC for 24hours under a humidified 
atmosphere of 5% CO2 to allow for acclimatisation.  
4.2.2 Quantification of nitric oxide production 
After 24 hours (the cells had adhered to the surface), 100μl of the cells each were taken and 
put in separate wells in a 96 well culture plate. Fifty microliters (50μl) of lipopolysaccharide 
(LPS), at either 100μM  or 25μM, was added to each well together with 50μl of plant extracts 
(25 and 100µg/ml). The 96-well plates were then put back in the incubator at 37 oC for 24hrs. 
Aliquots (50μl) of the cells from each well were removed and added to 50μl of Griess reagent 
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(Sigma Cat# 03553) in another 96-well culture plate and incubated at room temperature for 
15 mins. The absorbance was read at 560nm in a microplate reader (Multiscan MS, 
Labsystems). All tests were done in triplicate. 
4.2.3 Cell viability assay using MTT 
   The cytotoxicity assay was carried out on the LPS -induced cells and those with plant 
extracts and controls using the MTT assay (Soromou et al, 2012). One hundred microliters 
(100μl) of RAW 264.7 cells were aliquoted into wells of a 96-well culture plate. One hundred 
microliters (100μl) of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide was 
added to each well and incubated at room temperature for 1 hour. The cell viability was 
measured at an optical density of 560 nm in a microplate reader (Multiscan MS, Labsystems ) 
All tests were done in triplicate. 
4.2.4 COX-2 assay 
   The RAW 264.7 cells were fixed in formaldehyde at two different concentrations (100μM  
and 25μM). The formaldehyde was removed by solubilizing in methanol (50μl), and the 
remaining RAW 264.7 cells  kept in the freezer at -20oC for 10 minutes. The cells were then 
washed with 50μl of 1% BSA solution and 50μl of 3% BSA and 0.2% Triton X100 added 
before incubating at room temperature for 45minutes. Fifty microliters (50μl) of antibody 
was added at 1: 800 dilution and the cells incubated for a further 1 hour. The cells were then 
washed twice with PBS before Hoechst solution with 3% BSA was added. The presence of 
the COX-2 was observed using a fluorescent microscope ( ImageXpress XLS Micro 
[Molecular Devices]). The absorbance was read at 560nm in a microplate reader (Multiscan 
MS, Labsystems). All tests were done in triplicate.The same procedure was carried out using 
the positive controls, aminoguanidine and celecoxib. Aminoguanidine is a selective inducible 
nitric oxide synthase inhibitor that prevented nitric oxide induced organ damage in 
experimental subjects as well as caused reduction in tumour growth in xenografted animals 
(Soliman, 2014; Basudhar et al, 2017); celecoxib is a selective COX-2 inhibitor that is used 
to treat pain and inflammation. COX-2 inhibitors have been shown to inhibit tumour growth 
in several animal models (Koki and Masferrer, 2002). In a study on ovarian cancer cell lines, 
celecoxib was shown to inhibit cell proliferation, induce apoptosis, G1 cell cycle arrest and 
reduce expression of COX-2 protein (Suri et al, 2016). Thus aminoguanidine and celecoxib 
are ideal controls for this study.  
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4.2.5 Statistical analysis 
Data obtained were presented as means ± SD. All experiments were done in triplicates. The T  
test were used to determine the differences among the means of the various samples. P values 
< 0.05 were regarded to be significant. 
 
4.3 RESULTS AND DISCUSSION 
4.3.1 Anti-inflammatory activity of Opuntia stricta  
    From this study, the Opuntia extracts had mild cytotoxic effects on the RAW 264.7 cells 
especially at 100 μM (Figure 15). These results proved that activities of Opuntia extracts 
were not as a result of a reduction in cell viability.  
   For the COX-2 assay (Figure 16), the numbers of cells that are viable were determined by 
the Hoechst staining of the nucleic acids as previously described (section 4.2.4).The Opuntia 
extracts had mild cytotoxic effects on the RAW 264.7 cells.The cytotoxic effects occurred 
mainly at a concentration of 100 μM (Fig 18). The results also showed that the activity of 
opuntia extracts was not as a result of a reduction in cell viability.  
 
 
Figure 15: The percentage viable RAW 264.7 cells after 24-hour incubation with either 25 or 
100µg/ml LPS and the Opuntia extracts. AG= Aminoguanidine. CELEX= Celecoxib. NE= 
No extract. 
Each value represents mean ± S.D (n=3) 
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Figure 16: RAW 264.7 cells density with Hoechst stain. (Opuntia stricta) 
AG= Aminoguanidine. CELEX= Celecoxib. NE= No extract. 
Each value represents mean ± S.D (n=3).  
 
4.3.2 Effect of Opuntia stricta extracts on LPS- induced Nitrous oxide production 
   The various levels of nitrous oxide released were measured by an ELISA reader. When LPS 
alone was added to the RAW 264.7 cells, there was increased production of nitrous oxide as 
compared to the addition of the plant extracts and the controls. (Figure 17). The level of 
nitrous oxide was significantly decreased (p< 0.05) in the plant extract groups and the 
controls when compared to LPS-induced only cells. The level of nitrous oxide was however 
higher and showed significant difference (p< 0.05) in the plant extracts compared to the 
control group. 
  4.3.3 Effect of Opuntia stricta extracts on COX-2 expression    
   The treatment of the RAW 264.7 cells with Opuntia stricta extracts caused a decrease in 
COX-2 expression in some of the wells (Figure 18). The acetone fresh and the aqueous fresh 
showed a COX-2 reduction of about 15% each which were comparable to celecoxib, a 
selective COX-2 inhibitor at 17%. These anti-inflammatory properties of Opuntia spp. was 
also reported by Siddiqui et al. (2016). The anti-inflammatory actions have been linked to 
several phytochemicals including beta-sitosterol which was not found in these extracts. 
Moosazadeh et al. (2014) also did not report beta-sitosterol in the Opuntia stricta fruits they 
studied. However indicaxanthin, a compound found in the fruits of Opuntia ficus indica has 
been shown to inhibit the mRNA expression of COX-2 and iNOS as well the proteins 
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prostaglandin E2, nitrous oxide, and interleukin- beta (Allegra et al., 2014).  These anti-
inflammatory properties of Opuntia spp. have long been exploited in traditional medicine for 
wound healing and treatment of burns and have been demonstrated at the molecular level 
(Nakahara et al., 2015). Opuntia stricta like most Opuntia spp. have equally shown good 
anti-inflammatory potentials as observed in this study. 
 
Figure 17: The effect of Opuntia stricta extracts on LPS- induced nitrous oxide production in 
RAW 264.7 cells. NE= No extract. AG= Aminoguanidine. CELEX= Celecoxib. NE= No 
extract. Values expressed as mean ± S.D (n=3).  
 
 
Figure 18: The effect of Opuntia stricta extracts on COX-2 expression in RAW 264.7 cells. 
NE= No extract. AG= Aminoguanidine. CELEX= Celecoxib. NE= No extract.Values 
expressed as mean ± S.D (n=3). 
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   During inflammation pro-inflammatory cytokines can be induced by LPS, which can cause 
an increased production of nitrous oxide and other inflammatory mediators which are needed 
to suppress the stimulus that most times is infectious. However uncontrolled production of 
these inflammatory mediators can lead to the systemic inflammatory response syndrome 
(SIRS) which can invariably lead to multi-organ dysfunction syndrome (MODS) and then 
death. It is thus imperative that the actions of these inflammatory mediators are tightly 
regulated. Some of these inflammatory mediators are also implicated in some inflammatory 
diseases (Farrugia and Baron, 2016), and are targets for pharmacological intervention 
(Perdriger, 2009). 
Targeting inflammatory mediators like nitrous oxide with natural products is not a novel idea. 
Opuntia spp. has been reported to have anti-inflammatory properties (Siddiqui et al., 2016; 
Santo- Diaz et al., 2017).  Polyphenols are known to perform many biological activities in the 
body. Quercetin has been shown to inhibit LPS-induced production of nitrous oxide (Ghosh 
and Manjeet, 1999; Kang et al., 2013).Compounds like germacrene-D, globulol and 
caryophyllene also found in Opuntia stricta have been shown to have good anti-inflammatory 
properties (Beg et al., 2011).  Isorhamnetin, a flavonoid glycoside found in different Opuntia 
spp. is also known to inhibit LPS- induced production of inflammatory mediators (Yang et 
al., 2013). In this study extracts from Opuntia stricta were able to inhibit LPS-induced 
nitrous oxide production with minimal cytotoxicity. The aqueous dried and the acetone fresh 
Opuntia stricta extracts were more efficacious in doing this than the other extracts. Opuntia 
stricta can, therefore, be considered as a viable medicinal plant in the management of 
inflammatory conditions.   
4.3.4 Anti-inflammatory activity of Pelargonium inquinans 
   The same procedure described in section 4.2 and 4.3.1 was carried out. The cell viability 
was measured by MTT assay. From the study, the Pelargonium extracts had profound 
cytotoxic effects on the RAW 264.7 cells especially at 100 μM (Figure 19). At 25 μM, the 
aqueous dried, ethanol dried, acetone fresh, aqueous fresh and ethanol fresh extracts also 
showed cytotoxicity (Fig 19).  These results suggest that activities of Pelargonium extracts 
were as a result of a reduction in cell viability. Hence measurement of inhibition of LPS-
induced nitrous oxide production may not be necessary.  
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Figure 19: The percentage viable RAW 264.7 cells after 24-hour incubation with 
Pelargonium extracts. Each value represents mean ± S.D (n=3).  
 
4.3.5. Effect of Pelargonium inquinans extracts on LPS- induced Nitrous oxide 
production    
 The level of nitrous oxide was significantly increased (P< 0.05) in the plant extract groups 
when compared to the LPS- induced cells alone and the controls. This effect was more 
evident in the dried aqueous and fresh ethanol extract than in the other extracts (Figure 20). 
These were equally among the extracts that had the highest effect of cytotoxicity on the RAW 
264.7 cells after 24-hour incubation 
    The ability to increase nitrous oxide production in macrophages can be viewed as pro-
inflammatory and was reported for Pelargonium sidoides extract EPS® 7630 as well(Conrad 
et al, 2007). This extract was shown to increase cellular nitrous oxide production and mRNA 
iNOS levels in Leishmania major-infected murine macrophages (Trun et al., 2006; Witte et 
al., 2015). Several other cytokines with immunostimulatory properties were also stimulated 
by EPS® 7630 and Pelargonium reniforme extracts (Kolodziej and Kiderlen, 2006). Many of 
these inflammatory mediators like interleukin 1,2 6 and TNF -alpha released are 
proinflammatory. However the anti-inflammatory cytokine, IL-10 was also produced. The 
EPS® 7630 has been shown to carry out these function largely through the activation of 
MAP kinase pathways, and slight activation of the PI3K (phosphorylation of Akt) and NF-κB 
(phosphorylation of p65) pathways (Witte et al., 2015). It is possible that the increased 
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production of  nitrous oxide observed in some Pelargonium inquinans extracts are a result of 
their proinflammatory activities just like it was observed in Pelargonium sidoides herbal 
extract. More studies will have to be done to prove it.  
 
Figure 20: The effect of Pelargonium inquinans extracts on LPS- induced nitrous oxide 
production in RAW 264.7 cells. NE= No extract. AG= Aminoguanidine. CELEB= 
Celecoxib. Values expressed as mean ± S.D (n=3). 
 
  4.3.6 Effect of P. inquinans extracts on COX-2 expression    
    For the COX-2 assay, the number of cells that are viable were determined by the Hoechst 
staining of the nucleic acids as previously described. The Hoechst stain shows a relative 
decrease in the number of viable nuclei of the RAW 264.7 cells by all the P. inquinans 
extracts as compared to the control (Figure 21). Therefore it implies it has some cytotoxic 
effects on the RAW 264.7 cells at all the concentrations used in this study. The decrease was 
statistically significant (P < 0.05).  
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Figure 21: RAW 264.7 cells density with Hoechst stain. (Pelargonium inquinans). NE= No 
extract. AG= Aminoguanidine. CELEX= Celecoxib.  
Values expressed as mean ± S.D (n=3). 
 
   The treatment of the RAW 264.7 cells with Pelargonium inquinans extracts caused a 
decrease in COX-2 expression in nearly all the wells (Figure 22). Except for the lower 
concentration (25g/ml) of the fresh ethanol extract, all other concentrations inhibited COX-2 
expression. The fresh acetone extract and the acetone dried extract showed more anti- COX-2 
inhibition than celecoxib and were of almost equal inhibition strength with 
aminoguanidine(Figure 22). The Pelargonium spp are known to have anti-inflammatory 
properties. For example, crude extracts of Pelargonium graveolens have recently been shown 
to inhibit prostaglandins and thromboxanes- end products of the COX-2 pathway -production 
in RAW 264.7 cell culture (Martins et al, 2017). A nanoemulsion containing geranium oil in 
macrophages was shown to inhibit COX-2 gene expression as well as other inflammatory 
mediators (Giongo et al, 2017). The essential oils of Pelargonium spp are famed for their 
soothing and anti-inflammatory effects (Boukhatem et al., 2013).  Eugenol, a phenylpropene 
also detected in our study is known to inhibit COX-2 expression in RAW 264.7 cells (Kim et 
al., 2003). Nerolidol, a sesquiterpene alcohol also discovered in this study and widely used in 
the food and cosmetics industry is reported to have both anti-nociceptive and anti-
inflammatory activity (Chan et al., 2016). Humulene, also another sesquiterpene found in this 
study has been shown to inhibit the expression of both COX-2 and iNOS (Fernandes et al., 
2007). The polyphenol-rich plants like Pelargonium have been shown to inhibit nitrous oxide 
production as well as have immunomodulatory properties (Kim et al., 1999; Kolodziej et al., 
2005).  
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 Pelargonium inquinans from our study has shown it has anti-inflammatory properties that 
can be further explored. 
 
Figure 22: The effect of Pelargonium inquinans extracts on COX-2 expression in RAW 
264.7 cells. NE= No extract. AG= Aminoguanidine. CELEX= Celecoxib. (PED- ethanol 
extract of dried Pelargonium; PWF- aqueous extract of fresh Pelargonium; PAF- acetone 
extract of fresh Pelargonium; PWD- aqueous extract of dried Pelargonium; PAD- acetone 
extract of dried Pelargonium; PEF- ethanol extract of fresh Pelargonium). 
Each value represents mean ± S.D (n=3).  
 
 
4.4 CONCLUSION 
   Medicinal plants have been well documented for their activities against inflammation and 
its associated stimuli. The Pelargonium spp. and the Opuntia spp. have been used as 
traditional medicines to treat various diseases.   In summary, this study has shown that 
Opuntia stricta extracts like some other Opuntia spp. have anti-inflammatory properties. 
Pelargonium inquinans extracts exhibited pro-inflammatory properties just like Pelargonium 
reniforme and Pelargonium sidoides extracts and also have anti-inflammatory properties 
especially with some of the compounds discovered in its essential oils. Further studies can 
still be carried out to ascertain the different mechanisms of inhibition and signal transduction 
pathways, as well as isolate the particular compounds responsible for these activities. This 
study also reveal P. inquinans have cytotoxic potentials. 
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CHAPTER 5 
5.1 Introduction 
      Cancer is one of the leading causes of mortality around the world despite advances in 
medical sciences. Great strides have been made in the discovery of newer treatments, but this 
comes at a cost and with life threatening side effects. Over the past decades, more emphasis 
has been laid on cancer prevention through the adoption of different approaches. The World 
Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) 
brought out an expert report in 2007 titled: "Food, Nutrition, Physical activity and the  
Prevention of Cancer: a Global Perspective " (2007). Among their many recommendations 
was the role of food, nutrition on cancer aetiology and cancer prevention. Data from the 
Comparative Risk Assessment project estimated that modifiable behaviours like smoking, 
alcohol use and low intake of fruits and vegetables were the leading risk factors for cancer 
deaths worldwide (Danaei et al., 2005). The role of these modifiable behaviours has led to 
more interest in cancer prevention research. Research into cancer prevention can be graded 
into three levels: primary (deals with the avoidance of potential carcinogens), secondary 
(deals with early screening, detection, and management of pre-cancerous lesions), and tertiary 
(deals with the management of cancer progression, relapse, and disease-related 
complications). Among the well-studied modifiable factors are phytochemicals (Gonzalez-
Vanillas et al., 2013).  
   Phytochemicals are compounds without any nutritive values but have been shown to serve 
as chemoprophylaxis against some diseases. They are found in various types of fruits and 
vegetables and are the key biochemical factors discovered in different epidemiological 
studies as the link between fruits and vegetable consumption and reduction in developing 
some diseases including cancer (Key et al., 2009). They are known to be active in various 
stages of cancer prevention, and their roles have opened up new areas of research especially 
in the "omics" (nutriproteomics, nutritranscriptomics, nutrigenomics, nutrimetabolomics). 
Primarily, a large proportion of activity found in medicinal plants are as a result of 
phytochemicals, which over the centuries have been used in folklore medicine for the 
management of cancer because of cost, low toxicity, and availability.  
   A number of these phytochemicals have been developed as drugs for the management of 
various cancers. It is reported that about 40% of drugs approved by the United States Food 
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and Drug Administration (FDA) are phytochemical based (Kinch et al., 2014). Few examples 
of some of the phytochemicals that made it as antineoplastic agents include the alkaloids 
vincristine and vinblastine from the medicinal plant Catharanthus roseus, and the lignan 
derivative etoposide from the medicinal plant Podophyllum peltatum (Cragg and Pezzuto, 
2016). A good number are still in various clinical trials to ascertain their efficacy. For 
example dimethylaminoparthenolide, a parthenolide analogue is currently in phase II clinical 
trial for acute myeloid leukaemia (Siveen et al., 2017). Phytochemicals are being subjected to 
modern scientific approaches to elucidate their mechanism of action. Some of these actions 
include induction of apoptosis, cell cycle arrest, inhibition of angiogenesis, cellular 
differentiation and inhibition of growth signals. Anti-inflammatory and anti-oxidant activities 
are also means to prevent cancer growth as some cells initiate cancer through oxidation and 
inflammation (Rakoff-Nahoum, 2006; Reuters et al., 2010).  
   South Africa has a large flora with over 20,000 different species (Cherry, 2005), but only a 
few species have made it as medicinal products (Van Wyk, 2011). Although some 
phytochemicals from medicinal plants have been translated into modern antineoplastic drugs, 
very few of these plants have been found in South Africa (Steenkamp and Gouws,2006). An 
in vitro anticancer screening done on 7,500 extracts by Fouche et al. (2008) against a panel of 
sixty human cancer cell lines showed that only 5.9% had moderate anticancer activity. An 
example is combretastatin, a stilbene from the Eastern Cape bush willow tree, Combretum 
caffrum, which is currently in the Phase 2/3 FOCUS trial for the treatment of resistant ovarian 
cancer (Chase et al., 2017).  In vitro screening of medicinal plants for an antineoplastic 
activity like in this study can be a good step in the discovery of lead compounds from South 
African plants.  
5.2 Materials and methods 
5.2.1 Cytotoxicity test 
   Fresh and dried plant extracts of the various solvents (aqueous, acetone & ethanol) were 
weighed and dissolved in dimethyl sulfoxide (DMSO). They were then all sonicated for 
proper solubilization and stored at -20oC. The plant extracts were then diluted in RPMI-1640 
supplemented with 5% fetal bovine serum (FBS) and streptomycin medium to its final 
concentrations. 
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   The U937 and Jurkat cell lines used were obtained from the Department of Biochemistry, 
Nelson Mandela University, South Africa. The cell lines were maintained in RPMI-1640 
(Hyclone Labs, Cat 30255) medium supplemented with 5% FBS and penicillin/streptomycin 
(Biowest, Cat S181G-100). The cell count was done using a Neubauer counting chamber 
after it was stained with trypan blue to detect viable cells. Afterwards, the cells were plated at 
a density of 2.5 x 104 cells/well in a 96-well plate and cultured overnight in an incubator at 
37oC. After 24hrs the plant extracts were added at various concentrations (12.5,25,50, 100, 
and 200 μg/ml for U937;  25,50, 100 and 200 μg/ml for Jurkat), then the cells were incubated 
for another 48 hrs. After the 48hrs, 10μl of the tetrazolium dye  3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) was added to each well, and the plate further 
incubated at 37oC for 4hrs. The absorbance was determined using an ELISA reader 
(Multiscan MS, Labsystems) at a wavelength of 560nm. All the tests were done in triplicate. 
Cytosine arabinoside was used as a positive control. The data obtained were subjected to 
statistical analysis to determine the concentration of the extracts required to cause reduction 
of 50% viability for each cell line.  
5.2.2 Cell cycle analysis 
   The medium was prepared in the same way as described in section 5.2.1. 50 μg/ml of 
extracts and control were used. The cell lines (U937 and Jurkat) were incubated with the 
extracts/controls overnight. After 24hrs, the cells were then stained with propidium iodide 
and then incubated for ten min. The cell cycle distribution was analysed using flow cytometry 
(Cytomics FC500). 
5.2.3 Statistical analysis 
Data obtained were presented as means ± SD. All experiments were done in triplicates. The T  
test were used to determine the differences among the means of the various samples. P values 
< 0.05 were regarded to be significant. 
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5.3 Results and discussion 
5.3.1 Cytotoxic effect of Opuntia stricta extracts on U937 cell line 
   The MTT assay carried out to determine the cytotoxic effects of the various Opuntia stricta 
extracts on the U937 cell line showed that after 48hrs none of the extracts displayed cytotoxic 
effect. Hence a cell cycle analysis was unnecessary. However, at concentrations of 100 and 
200μg/ml, the acetone dried extract displayed some activities as indicated in Table 14 and 
Figure 23 below. The table clearly shows O. stricta extracts are not cytotoxic to U937 cells. 
This may be as a result of low levels of polyphenol or because the cell type is resistant to the 
compounds present in the extracts. Some Opuntia spp. are also known to have 
immunomodulatory effects on cells with the release of proinflammatory cytokines that 
enhances growth (Schepetkin et al, 2008). 
TABLE 14: Cytotoxic effect of Opuntia stricta cladode extracts on U937 cell line after 48hrs  
                 Values expressed as mean ± S.D (n=3).  
 
Conc. 
(μg/ml) 
% 
control 
Acetone 
dried 
Aqueous 
dried 
Ethanol 
dried 
Acetone 
fresh 
Aqueous 
fresh 
Ethanol 
fresh 
0 100       
12.5  126.06± 5.5 115.07±9.2 102.24±19.6 89.96±8.8 98.39±20.4 122.91±6.9 
25  111.13± 6.8  112.69±22.7 99.86±12.7 105.1±2.6 95.98±8.6 109.25±5 
50  116.96± 2.6 113.22±12.5 102.42±17.8 104.47±4.9 116.97±16.4 119.79±13.3 
100  46.84±13.6 139.96±23.8 109.08±12.3 118.47±4.6 103.6±4.5 118.88±2.6 
200  30.16±0.8 148.46±27.7 109.51±9.15 116.04±4.9 99.47±4.5 121.4±10.7 
 
 
Figure 23: Cell viability of acetone fraction of the dried extract of Opuntia stricta.                 
Values expressed as mean ± S.D (n=3).  
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5.3.2. Cytotoxic effect of Opuntia stricta extracts on Jurkat cell line 
     The MTT assay carried out to determine the cytotoxic effects of the various Opuntia 
stricta extracts on the Jurkat cell line showed that after 48hrs only the fresh extracts of the 
three solvents (acetone, aqueous, ethanol) used displayed slight cytotoxic effect as indicated 
in the table and figures below (P> 0.05). Hence a cell cycle analysis was unnecessary.   
TABLE 15: Cytotoxic effect of Opuntia stricta cladode extracts on Jurkat cell line after 48h  
                   Values expressed as mean ± S.D (n=3).  
 
Conc. 
(μg/ml) 
% control Acetone 
dried 
Aqueous 
dried 
Ethanol 
dried 
Acetone 
fresh 
Aqueous 
fresh 
Ethanol 
fresh 
0 100       
25  91.52±2.6 90.9±3.4 94.04±7.5 96.5±8.3 94.11±5 89.04±5.5 
50  103.78±3.5 88.16±10.4 102.52±5.8 99.9±3.3 79.53±9.1 90.5±5.7 
100  94.59±12 93.7±3.1 112.03±8.8 88.43±13 77.26±3.9 90.37±6.3 
200  125.64±9.2 119.96±12.6 113.57±7.7 83.33±1.28 68.99±3.3 98.8±7.18 
 
 
Figure 24a: Cell viability of acetone fraction of the fresh extract of Opuntia stricta (OAF).                 
Values expressed as mean ± S.D (n=3).  
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Figure 24b: Cell viability of aqueous fraction of the fresh extract of Opuntia stricta(OWD).                 
Values expressed as mean ± S.D (n=3).  
 
 
Figure 24c: Cell viability of ethanol fraction of the fresh extract of Opuntia stricta(OEF).                 
Values expressed as mean ± S.D (n=3).  
 
The non-cytotoxic effect of the cladodes of Opuntia stricta against Jurkat and U937 cell lines 
may just be that it lacked compounds in sufficient amount with cytotoxic activity. This can be 
explained by the low levels of phytochemicals it yielded when compared to the polyphenolic 
rich Pelargonium in this study. This non-cytotoxicity was also observed by Gebresamuel and 
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Recently Harrabi et al. (2017) reported the cytoprotective effect of Opuntia stricta cladodes 
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  However, the ethyl acetate fraction of Opuntia stricta flower extract was reported to have 
antineoplastic activity against HepG2 cell line (Prabhakaran et al., 2017). Betalains, which 
are water-soluble nitrogenous pigments present in flowers and fruits of Opuntia spp., have 
also been reported to have good antineoplastic activity against some cancers (Nowacki et al., 
2015; Farabegoli et al., 2017). Betalains from the fruit of Opuntia ficus indica was shown to 
induce apoptosis in chronic myeloid leukaemia, K562 cell line (Sreekanth et al., 2007). 
Opuntia stricta is known to have the highest total betalain content among all the Opuntia spp. 
studied (Santo Diaz et al., 2017). So it is possible some other parts of the plants have 
compounds with antineoplastic activity. 
5.3.3 Cytotoxic effect of Pelargonium inquinans extracts on U937 cell line 
   The MTT assay carried out to determine the cytotoxic effects of the various Pelargonium 
inquinans extracts on the U937 cell line showed that the extracts had good cytotoxic activity 
on the cell line after 48h. All the fractions of the extracts showed activity against U937 cell 
line (Fig 25 a,b,c,d,e,f). However, the aqueous dried extract showed the greatest activity 
killing about 80% of the cell at a concentration of 50 μg/ml in 48h. The fresh acetone extract 
and the fresh aqueous extract also showed good anti-cancer activity.Table 16 lists their IC50 
values.  
 
   
Figure 25a: Cell viability of acetone fraction of the dried extract of Pelargonium inquinans 
(PAD).                  
Values expressed as mean ± S.D (n=3).  
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 Figure 25b: Cell viability of aqueous fraction of the dried extract of Pelargonium 
inquinans(PWD).                 
 Values expressed as mean ± S.D (n=3).  
 
 
Figure 25c: Cell viability of ethanol fraction of the dried extract of Pelargonium 
inquinans(PED).                  
Values expressed as mean ± S.D (n=3). 
 
 
Figure 25d: Cell viability of aqueous fraction of the fresh extract of Pelargonium inquinans 
(PWF).                  
Values expressed as mean ± S.D (n=3). 
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Figure 25e: Cell viability of acetone fraction of the fresh extract of Pelargonium inquinans 
(PAF).                  
Values expressed as mean ± S.D (n=3). 
 
 
Figure 25f: Cell viability of ethanol fraction of the fresh extract of Pelargonium inquinans 
(PEF).                  
Values expressed as mean ± S.D (n=3). 
 
 
 
 
 
Table 16: In vitro cytotoxicity result for Pelargonium inquinans extracts on U937 cells 
 
Extracts IC50 (μg/ml) 
Acetone dried 
Aqueous dried 
Ethanol dried 
Aqueous fresh 
Acetone fresh 
 
61.78 
3.34 
56.7 
26.3 
46.97 
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   5.3.4. Cytotoxic effect of Pelargonium inquinans extracts on Jurkat cell line 
      The MTT assay carried out to determine the cytotoxic effects of the various Pelargonium 
inquinans extracts on the Jurkat cell line showed that the extracts had moderate cytotoxic 
activity on the cell line after 48hrs. All the fractions of the extracts showed activity against 
Jurkat cell line (Fig 28 a,b,c,d,e,f). The ethanol and aqueous dried extract showed the greatest 
activity. Other fractions as well showed some activity. Table 17 lists their IC50 values.  
 
 
Figure 26a: Cell viability of ethanol fraction of the fresh extract of Pelargonium 
inquinans.(PEF)                  
Values expressed as mean ± S.D (n=3). 
 
 
Figure 26b: Cell viability of acetone fraction of the fresh extract of Pelargonium 
inquinans.(PAF)                  
Values expressed as mean ± S.D (n=3). 
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Figure 26c: Cell viability of aqueous fraction of the fresh extract of Pelargonium inquinans. 
(PWF)                  
Values expressed as mean ± S.D (n=3). 
 
Figure 26d: Cell viability of ethanol fraction of the dried extract of Pelargonium inquinans. 
(PED)                 
Values expressed as mean ± S.D (n=3). 
 
 
Figure 26e: Cell viability of aqueous fraction of the dried extract of Pelargonium inquinans. 
(PWD)                 
Values expressed as mean ± S.D (n=3). 
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Figure 26f: Cell viability of acetone fraction of the dried extract of Pelargonium 
inquinans.(PAD). Values expressed as mean ± S.D (n=3). 
 
 
 
Table 17: In vitro cytotoxicity result for Pelargonium inquinans extracts on Jurkat cells 
 
Extracts IC50 (μg/ml) 
Acetone dried 
Aqueous dried 
Ethanol dried 
Aqueous fresh 
Acetone fresh 
Ethanol fresh 
153.1 
38.44 
111.8 
221.4 
143.4 
362.3 
 
 
5.3.5. Cell cycle analysis 
  The cell cycle is most often seen as the time clock that regulates cell proliferation.Some 
compounds cause cytotoxicity to cells by impairing the cell cycle processes, thus inducing 
apoptosis. To better understand the cytotoxic activity of Pelargonium inquinans, DNA 
contents of the cell lines were examined after they were incubated with the different extracts. 
The results showed that the plant extracts-treated cells accumulated DNA in the G0/G1 and 
the sub-G1 phases of the cell cycle (Fig 27, 28). An aggregate analysis show that the cell 
lines treated with different Pelargonium inquinans extracts accumulated in the G0/G1 and 
sub-G1 phases with a concurrent reduction in the G2/M phase. Thus Pelargonium inquinans 
extracts induce apoptosis in Jurkat and U937 cell lines. 
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   The effect of the plant extracts on the cleavage of caspase 3 was analysed to highlight the 
mechanism of cell death in the cell lines since the end point of both the intrinsic and extrinsic 
pathway of apoptosis is caspase 3. The activation of caspase 3 was observed with some 
extracts on the U937  cells. The fresh ethanol and the fresh acetone extracts were able to 
activate caspase 3 (Figure 31). 
 
  
Figure 27: Cell cycle analyses of U937 cells at the sub-G1 phase. (PED- ethanol extract of 
dried Pelargonium; PWF- aqueous extract of fresh Pelargonium; PAF- acetone extract of 
fresh Pelargonium; PWD- aqueous extract of dried Pelargonium; PAD- acetone extract of 
dried Pelargonium; PEF- ethanol extract of fresh Pelargonium). 
Values expressed as mean ± S.D (n=3). 
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Figure 28: Cell cycle analyses of Jurkat cells at the sub-G1 phase. (OAF- acetone extract of 
fresh Opuntia; OWF- aqueous extract of fresh Opuntia; OEF- ethanol extract of fresh 
Opuntia; PWF- aqueous extract of fresh Pelargonium; PAF- acetone extract of fresh 
Pelargonium; PEF- ethanol extract of fresh Pelargonium). 
Values expressed as mean ± S.D (n=3). 
 
 
Figure 29: Cell cycle analyses of U937 cells at the G0/G1, S, and G2/M phases. (PED- 
ethanol extract of dried Pelargonium; PWF- aqueous extract of fresh Pelargonium; PAF- 
acetone extract of fresh Pelargonium; PWD- aqueous extract of dried Pelargonium; PAD- 
acetone extract of dried Pelargonium; PEF- ethanol extract of fresh Pelargonium; Cyt- 
Cytarabine). 
 
Values expressed as mean ± S.D (n=3). 
 
Figure 30: Cell cycle analyses of Jurkat cells at the G0/G1, S and G2/M phases. (OAF- 
acetone extract of fresh Opuntia; OWF- aqueous extract of fresh Opuntia; OEF- ethanol 
extract of fresh Opuntia; PWF- aqueous extract of fresh Pelargonium; PAF- acetone extract 
of fresh Pelargonium; PEF- ethanol extract of fresh Pelargonium) 
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Values expressed as mean ± S.D (n=3). 
 
 
Figure 31: Caspase 3 activation of U937 cells treated with Pelargonium inquinans extracts. 
(PED- ethanol extract of dried Pelargonium; PWF- aqueous extract of fresh Pelargonium; 
PAF- acetone extract of fresh Pelargonium; PWD- aqueous extract of dried Pelargonium; 
PAD- acetone extract of dried Pelargonium; PEF- ethanol extract of fresh Pelargonium; Cyt- 
Cytarabine). 
 
Values expressed as mean ± S.D (n=3).   
 
  The cytotoxic effect observed in the leaves of Pelargonium inquinans can be attributed to  
its high polyphenolic compounds. Similar antineoplastic effects have been observed in plant 
extracts rich in polyphenolic compounds. For example, extracts of green tea which is rich in 
polyphenolics have shown antineoplastic activity in certain cancer cell lines including 
leukaemia cell line (Yang et al., 1998; Li et al., 2000). Extracts from berries that are also rich 
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cells. Pelargonium quercetorum has been shown to induce apoptosis in lung cancer cell lines 
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cytotoxicity against MCF-7  cell lines (Al-Saffar et al., 2016). The cytotoxicity was in a dose-
dependent manner. In a  study of 21 Pelargonium spp. for cytotoxicity, the acetone extract of 
Pelargonium sublignosum and citrollenum displayed the highest cytotoxicity at IC50 of 11.89 
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Pelargonium sidoides. The tincture inhibited Jurkat cell line with an IC50 of 6.2 μg/ml 
(Pereira et al., 2016). The Pelargonium spp. are also rich in polyphenolics which may explain 
some of their antineoplastic activities. Natural compounds in them including gallic acid have 
been observed to inhibit cancer cells in vitro particularly Jurkat and HL-60 leukaemia cells 
(Yeh et al., 2011; Sourani et al.,2016). Some of these inhibitory activities were achieved 
through the inhibition of cyclin D and E and activating the mitochondrial inhibition pathway. 
   Similarly, the hydroxycoumarins have been shown to induce apoptosis in leukemia cell 
lines. Esculetin (6,7-dihydroxycoumarin) induced G1 phase cell cycle arrest in HL-60 
leukaemia cells (Wang et al., 2002). Similarly 7,8- dihydroxycoumarin induced apoptosis in 
U937 cell line (Riveiro et al., 2008).  In recent reports, esculetin has been shown to cause cell 
death through redox imbalance (Rubio et al., 2017; Rubio et al., 2017). The Pelargonium spp. 
are known to be rich in coumarins (Saraswathi et al., 2011). Mass spectrometry analysis of 
Pelargonium sidoides revealed that it was rich in sulfated coumarins like 5,6-
dimethoxycoumarin 7-sulphate, and 6,7-dihydroxycoumarin 8-sulphate (Pereira et al., 2016).  
   Crude extracts are usually considered for further analysis when their IC50  is less than 30 
μg/ml (Steenkamp and Gouws, 2006). Cell cycle analysis is usually done first. The G1 phase 
is usually characterized by protein synthesis towards cell division. In a recent study, cancer 
cells were observed to migrate more rapidly in the G0/G1 phase than in the S/G2/M phase; 
they were also more resistant to cytotoxic drugs in the G0/G1 phase (Yano et al., 2014). Thus 
targeting the G1 phase of the cell cycle is seen as a viable option in cancer management (Owa 
et al., 2001). Flavopiridol, a flavonoid, and a pan-CDK inhibitor showed significant activity 
in chronic lymphoid leukaemia, though with overt toxicities (Wiernik, 2016).  Cell cycle 
progression in the G1 phase is regulated by CDK 4 and 6 and palbociclib a CDK4/6 inhibitor 
have been shown to have activity in acute myeloid leukaemia (Uras et al., 2016).  In this 
study, crude extracts of Pelargonium inquinans were observed to cause G1 cell cycle arrest in 
both Jurkat and U937 cell lines.  
5.4 CONCLUSION 
   The results obtained from this study have shown that crude extracts of P. inquinans leaves 
have antineoplastic activity. They were able to reduce growth in the leukaemia cell lines. 
Their actions were more pronounced in the U937 cell line than in the Jurkat cell line. In both 
cases, they caused G1 cell cycle arrest and induced apoptosis (sub-G1). These actions might 
be as a result of the high levels of total phenols and flavonoids observed in this study. Further 
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work will need to be done to isolate and characterize the bio-active compounds in the plants 
as well as identify their mechanism of action.  
   Other parts of the plants like the flower and the roots that were not studied in this work can 
be explored to understand the pharmacological activities of this plant. A search of the 
literature showed there is a paucity of information on Pelargonium inquinans, albeit its 
pharmacological activities. This work apparently is the first to study the antineoplastic 
activity of Pelargonium inquinans. 
   The crude extracts of Opuntia stricta cladodes showed little to no cytotoxicity which, may 
be as a result of low amounts of polyphenolic compounds present in it. However, some other 
studies have shown that the flowers and fruits may have potential cytotoxic activity. 
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CHAPTER 6 
General discussion 
   Leukaemia is the most common childhood cancer (Jin et al., 2016) accounting for about 
30% of all paediatric cancers. The majority of the leukaemia cases are acute lymphoblastic 
leukaemia (ALL). Although ALL is potentially curable in children, the outcome in acute 
myeloid leukaemia (AML) is still poor. In adults, both types of acute leukaemia have a poor 
prognosis. While chemotherapy remains the mainstay of treatment, cases of drug resistance 
and disease relapse still pose a problem. Phytomedicine remain a viable option in the 
management of leukaemias and has been so for a long time. Many modern drugs used to 
manage leukaemia are a product of medicinal plants.  For example, Vincristine, an alkaloid 
widely used in the management of all types of leukaemia, is obtained from the leaves of the 
Madagascar periwinkle and Catharanthus roseus.  
   Phytomedicine has the potential to play a complimentary role in the management of 
leukaemias. In some countries, it is already part of mainstream healthcare. In this study, the 
antioxidant, anti-inflammatory and antineoplastic potentials of Opuntia stricta and 
Pelargonium inquinans extracts were investigated. The phytochemicals that were possibly 
responsible for these activities were also discussed. 
Phytochemicals 
   Phenolics, flavonoids, alkaloids, saponins, flavonol, proanthocyanidins, tannins and phytate 
were all found as part of the compounds present in the plants studied. They have been 
reported for their various biological activities which include antioxidation, anti-inflammatory 
and antineoplastic. These properties are part of what makes them appealing in phytomedicine 
and as such has led to the isolation of different compounds, some of which have found their 
way into clinical studies. Elucidation of their molecular mechanisms of action is an area of 
intense research. 
Antioxidant activity 
Oxidative stress is known to play a contributory role in leukaemia, just like in others cancers. 
It is known that increased level of ROS with a redundant antioxidant system can contribute to 
oxidative stress in leukemia cells (Zhou et al., 2017). Exogenous antioxidants have attracted 
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interest to reverse the process of oxidative stress. Phenolics and flavonoids are known to be 
able to interact with ROS and halt the process of oxidation before the cell is adversely 
affected (Kumar and Pandey, 2013). Polyphenols are also known to lower the catalytic 
activity of enzymes involved in ROS production (Hussain et al., 2016). In this study, the 
acetone, aqueous and ethanol extracts of Opuntia stricta and Pelargonium inquinans all 
showed strong antioxidant activity. This in vitro activity can be as a result of the polyphenols 
present in the plants. This makes both plants evaluated excellent candidates as sources of 
exogenous antioxidants. Further studies however, are required to confirm their activities and 
mechanisms of action of specific small molecules isolated from the plants. 
Anti-inflammatory 
   Anti-inflammatory activity was reported for both plants. They achieved this by blocking 
key enzymes and metabolites that play a role in the process of inflammation. Opuntia stricta 
extracts suppressed COX-2  expression and inhibited NO production. While Pelargonium 
inquinans was able to suppress COX-2 expression and increased NO production. This 
proinflammatory feature serves as a key immunomodulatory function that can be explored to 
fight leukaemias (Ustun et al., 2011).  Polyphenols have been reported to regulate the activity 
of different inflammatory mediators like cytokines, metabolites, peptides and even some 
transcription factors (Kim et al., 2009).  These various anti-inflammatory compounds are 
present in these plants. While this study focused only on COX-2 and NO, cytokines such as 
IL1,6 and TNF- alpha and transcription factors NF-kB, AP-1 can also be investigated in the 
future, to see if these plants' extracts also exhibit anti-inflammatory activity on them too. 
Antineoplastic 
   Diets rich in fruits and vegetables have been reported to reduce the risk of various cancers 
(Zhou et al., 2016) which has been attributed, to a certain extent, to polyphenols. Oxidative 
stress and inflammation play a key role in carcinogenesis, therefore the effect of polyphenols 
on these two activities means they play different roles in cancer. While Pelargonium 
inquinans is the only plant in this study that showed antineoplastic activity, the antioxidant 
and the anti-inflammatory activity of Opuntia stricta should not be overlooked. The 
antineoplastic activity of Pelargonium inquinans is evident with its cytotoxicity and ability to 
induce cell cycle arrest. The IC50 of the plant extract of less than 30 mg/ml is a good 
indication that Pelargonium inquinans needs to be further evaluated as a potential candidate 
for new drugs to treat leukaemia.  
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  Some components of the plant's essential oils have also been shown to have antineoplastic 
activity (Nibret and Wink, 2010).  Investigating these compounds would be an area for future 
research. 
Conclusion and Recommendation 
   While this study has partially justified the evaluation of these plants as potential 
antineoplastic materials, it is however recommended that further research be carried out on 
their mechanism of action. This may involve research into areas like genomics, proteomics, 
transcriptomics, metabolomics as well as signal transduction pathways. In vivo studies in 
mouse models can also be done. Finally, isolation and characterization of bioactive 
compounds for their biological activities are of utmost importance. 
    
